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ABSTRACT 
Mesenchymal stem/stromal cells (MSCs) are multipotent adult stem cells that hold 
enormous therapeutic potential. They are currently in a focus of intense clinical and 
scientific investigation. MSCs are a promising cell type for various applications in 
the field of tissue engineering due to their multi-lineage differentiation capacity. 
Furthermore, one of their most interesting characteristics is that they possess 
immunomodulatory properties making these cells an attractive candidate for therapy 
of several immune-mediated disorders. MSCs are of nonembryonic origin and thus 
provide a less controversial and technically more feasible alternative for ESCs in 
future therapeutic applications.  
 
Due to their location on the cell surface, glycans are ideal molecules for 
identification, purification, and characterization of cells for therapeutic purposes. 
Methods to reliably and proficiently determine both the change in the presence of a 
specific glycan structures and the changes in the glycome profile of a cell, are 
needed. Glycan binding proteins in general serve as diagnostic tools in medical and 
scientific laboratories. High affinity and exquisite specificity are important factors 
for their successful use.  
 
The aim of this study was to characterize the glycans on the surface of MSCs in 
order to find novel MSC specific glycan markers. Further goal was to develop 
antibodies specific for MSC surface glycans, including the novel MSC marker.  
 
As described in the original publications of this study, we first characterized the 
glycome of MSCs and discovered that certain specific glycan epitopes are present 
only in MSCs, and not in cells differentiated from them. These epitopes include i 
antigen, which was further characterized to be a marker for umbilical cord blood 
derived MSCs. An antibody against the i antigen was generated using recombinant 
technology. Antibodies recognizing MSC surface glycans were also generated by 
utilizing hybridoma technology, using whole MSCs in the immunization.  
 
Taken together, these studies provide information of the changes in the glycome 
profile during MSC differentiation and describe a novel MSC marker. In these 
studies, we used two different methods to generate anti-glycan antibodies and 
emphasize the importance of thorough characterization of the binding properties of 
GBPs. The information of the characteristic glycosylation features of MSCs, and 
specific markers especially, can be used to isolate and characterize desired, 
therapeutically advantageous cell populations for distinct applications. Development 
of better glycan binding proteins will advance the field of cellular therapy and also 
the glycobiological research in general.   
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REVIEW OF THE LITERATURE 
1 MESENCHYMAL STEM CELLS 
1.1 Stem cell classes 
Stem cells are undifferentiated cells that are present throughout life, from embryo to 
adult. They are defined by their capacity for self-renewal, high differentiation 
potential, and their ability to differentiate into different progenitor and mature cell 
types. The classification of stem cells is based on their development potential. The 
most versatile cell type is the totipotent stem cell, e.g. the fertilized oocyte and cells 
in the early embryo, capable of giving rise to all embryonic and extraembryonic cell 
types. These cells are able to specialize and form the blastocyst. Embryonic stem 
cells from the inner cell mass of this blastocyst are called pluripotent, meaning they 
have the potential to develop into all different cell types found in an embryonic and 
adult organism, excluding extraembryonic organs, such as placenta and umbilical 
cord. Multipotent stem cells, such as mesenchymal stem/stromal cells (MSCs) and 
hematopoietic stem cells (HSCs) are able to differentiate into multiple, but limited 
cell types. Cells able to give rise to few or one specific cell lineages are called tissue-
specific progenitor cells (Alison et al. 2002).  
1.1.1 Human pluripotent stem cells 
Pluripotent human embryonic stem cells (ESCs) are, in theory, the most versatile cell 
type for application in regenerative medicine. ESCs can be grown from the inner cell 
mass of human embryos produced by in vitro fertilization (IVF). The first immortal 
human ESC lines were produced in 1998 (Thomson et al. 1998).  ESCs have been 
hailed as a promising source of therapy for a wide variety of human diseases, 
including Parkinson’s disease, diabetes mellitus and Alzheimer’s disease.  The 
ethical issues surrounding the use of IVF embryos, the lack of understanding how to 
specifically regulate ESC differentiation, and the widely reported tumorigenicity 
associated with ESC experimental models have driven researchers to use adult stem 
cells that lack these drawbacks (Salem and Thiemermann 2010).  
 
Few years ago researchers managed to reprogram human somatic cells into 
pluripotent state by retroviral transduction of just four genes of regulatory 
transcription factors; Oct4, Sox2, Klf4 and c-Myc (Takahashi et al. 2007, Park et al. 
2008). These cells are called induced pluripotent stem (iPS) cells. iPS cells can be 
used to generate patient- and disease-specific pluripotent stem cells, but there are 
number of challenges to overcome if iPS cells were to be applicable in regenerative 
medicine. Major concerns of iPS cells are caused by the low efficiency of iPS cell 
generation without genetic alterations, the possibility of tumour formation in vivo, 
REVIEW OF THE LITERATURE 
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the random integration of retroviral-based delivery vectors into the genome, and 
unregulated growth of the remaining cells that are partially reprogrammed and 
refractory to differentiation (Madonna 2012). The development of iPS cells has not 
replaced the use of human ESCs but has offered additional insights into 
understanding disease mechanisms and a suitable tool for personalized medicine 
such as drug screening and toxicology (Shtrichman et al. 2013).  
1.1.2 Adult multipotent stem cells 
HSCs and MSCs are non-embryonic, adult stem cells and thus provide a less 
controversial and technically more feasible alternative for embryonic stem cells in 
future therapy applications (Moore et al. 2006, Pessina and Gribaldo 2006). 
 
HSCs can differentiate to produce all mature blood cell types in the body. Human 
blood contains a large variety of differentiated cells with a limited half-life, therefore 
new blood cells need to be provided continuously by multipotent HSCs. The primary 
source of HSCs in the adult is the bone marrow, but HSCs from umbilical cord blood 
and peripheral blood are also clinically used (Arcese et al. 1998, Ng et al. 2004). It is 
known that a small number of HSCs can expand to generate a very large number of 
daughter HSCs as well as progenitor cells and differentiated blood cells. This 
phenomenon is utilized in bone marrow transplantation, where a small number of 
HSCs reconstitute the hematopoietic system after chemotherapy or irradiation used 
to destroy the patients own bone marrow. Today, HSC transplant is the only stem 
cell therapy widely used in clinical practice to treat patients with hematological 
malignancies (Helmy et al. 2010).  
 
MSCs are an excellent cell type for therapeutic applications, since they lack the 
ethical considerations of ESCs and the safety concerns of iPS cells. MSCs are 
multipotent cells originally isolated from the bone marrow and subsequently also 
identified in various other adult and fetal tissues (Kern et al. 2006, Campagnoli et al. 
2001, Tsai et al. 2004). MSCs are currently in a focus of intense clinical and 
scientific investigation. Due to their multi-lineage differentiation capacity, they are a 
promising cell type for various applications in the field of tissue engineering 
(Pittenger et al. 1999). MSCs have also been shown to be capable of improving 
engraftment of hematopoietic stem cells after allogeneic transplantation (Koc et al. 
2000, Dazzi et al. 2006). One of the most interesting features of MSCs is that they 
possess immunomodulatory properties and that makes these cells an attractive 
candidate for therapy of several immune-mediated disorders (English et al. 2010, Yi 
and Song 2012).  
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1.2 Characteristics of mesenchymal stem cells 
1.2.1 History 
MSCs were first identified from the bone marrow in the 1960s by McCulloch and 
Till, who first revealed the clonal nature of these cells (Siminovitch et al. 1963, 
Becker et al. 1963). MSCs were further investigated in the 1970s by Friedenstein and 
colleagues, who demonstrated their capacity for self-renewal and multi-lineage 
differentiation and named the cells colony-forming unit fibroblasts (Friedenstein et 
al. 1974, Friedenstein et al. 1987). The term mesenchymal stem cell, cell capable to 
differentiate into all cells of mesodermal lineage, was coined by Caplan in 1991 
(Caplan 1991). Caplan’s group was also the first one to isolate these cells from the 
human bone marrow (Haynesworth et al. 1992). Since then, MSCs have been 
isolated from number of other sources, including umbilical cord blood (UCB), 
adipose tissue, liver, and amniotic fluid (Kern et al 2006, Campagnoli et al. 2001,  
Tsai et al. 2004). The physiological role of MSCs in the bone marrow is thought to 
be the maintenance of the HSC microenvironment and the control of their 
quiescence or proliferation, differentiation and recruitment (Friedenstein et al. 1974, 
Dazzi et al. 2006, Uccelli et al. 2008). Nowadays, International Society of Cellular 
Therapy (ISCT) recommends the term multipotent mesenchymal stromal cell instead 
of mesenchymal stem cell (maintaining the acronym MSC) (Horwitz et al. 2005), to 
point out that these cells are a  heterogenous population of cells, not all of them 
necessarily having self-renewal capacity required for stem cells. Both terms are 
widely used in the literature.   
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 MSCs reside within the stromal compartment of bone marrow where they play a role in Figure 1
providing the stromal support system for HSCs. MSCs represent a very small fraction, 
0.001–0.01% of the total population of nucleated cells in marrow. However, they can be 
isolated and expanded with high efficiency, and induced to differentiate to osteoblasts, 
chondrocytes, and adipocytes under defined culture conditions (Barry and Murphy 2004). 
Modified from Uccelli et al. 2008 and Dazzi et al. 2006).  
1.2.2 Defined characteristics 
Biological and clinical interest in MSC has risen dramatically over last two decades, 
but the defining characteristics of MSC have been inconsistent among investigators. 
Many laboratories have developed methods to isolate MSCs. They have been 
isolated from many different sources and expanded in different culture conditions. 
Variations on methodologies and tissue sources result inevitably to a question 
whether the resulting cells are sufficiently similar to be compared for biological 
properties, experimental outcomes, and therapy applications. A particular challenge 
has been the absence of a specific marker to define MSCs. In 2006 the ISCT defined 
minimal criteria for MSCs (Dominici et al. 2006). According to these criteria MSCs 
have to be plastic adherent, and express surface antigens CD105, CD73, and CD90. 
MSCs have to lack the expression of CD45, CD34, CD14 or CD11b, CD79α or 
CD19 and HLAII (predominantly markers of hematopoietic cells), to exclude cells 
most likely to be found in MSC cultures. To meet the criteria, MSCs also have to be 
able to differentiate to osteoblasts, adipocytes, and chondroplasts. 
1.2.3 Heterogeneity 
Most of the research of MSCs is focused on bone-marrow derived MSCs (BM-
MSCs) and these are also overrepresented in clinical trials (Helmy et al. 2010, 
English et al. 2010). However, as other attractive sources for MSCs exist, these 
Osteoblast MSC HSC Adipocyte Chondrocyte
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should be thoroughly considered for their slightly different features and the 
availability of their source (Lv et al. 2012, Akimoto et al. 2013, Strioga et al. 2012). 
A source of MSCs could be selected according to the intented application. Based on 
their availability, umbilical cord blood and adipose tissue have become promising 
sources of MSCs (Kern et al. 2006).  
 
Even if MSCs isolated from different sources meet all the criteria required, the 
cells are not uniform (Kern et al. 2006). MSCs obtained from different tissues have 
been reported to have differences in gene expression, diverse differentiation 
potential, proliferation capacity, and differences in surface antigens other than stated 
in the requirements of minimal criteria (Kern et al. 2006, Lu et al. 2006, Alviano et 
al. 2007). Some of the differences may represent specific features of MSCs from 
different origins and some may be related to different isolation and culture protocols 
(Strioga et al. 2012).   
 
The culture expanded MSC population may be heterogeneous and represent 
several generations of different types of mesenchymal cell progeny with differing 
proliferation and differentiation potentials (Reiser et al. 2005).  Parameters such as 
plating density, number of passages, and especially culture medium may have 
profound effects to the cells (Sotiropoulou et al. 2006, Bieback et al. 2009). The cell 
culture conditions may influence the properties, especially immunomodulatory 
effects of MSCs even more than the MSC source (Helmy et al. 2010). Cells that are 
aimed at therapy applications, should be cultivated in a medium free of any animal 
derived substituents. These could result in the production of animal derived glycans, 
such as N-glycolylneuraminic acid (Neu5Gc), on the cell surface, potentially causing 
problems when the cells are given to a patient (Varki 2001, Heiskanen et al. 2007, 
Tangvoranuntakul et al. 2003).  
1.2.4 Plasticity 
The ability of MSCs to differentiate to other cell lineages than cells from 
mesodermal origin is called transdifferentiation, or plasticity. MSCs, being of 
mesodermal origin, have been reported to differentiate in vitro into endoderm and 
ectoderm lineages, including neural cells (Sanchez-Ramos et al. 2000, Krampera et 
al. 2007), hepatocytes (Schwarts et al. 2002), and epithelial cells (Spees et al 2003). 
Whether the plasticity is a relevant issue in vivo, is still controversial and differing 
opinions are found in the literature. Also, transdifferentiation may just be the result 
of prolonged culture expansion under specific culture conditions (Nauta and Fibbe 
2007, Fernandez Vallone et al. 2013).  
 
Plasticity was initially hailed as a promising property widely applicable 
therapeutically. More recent findings suggest that the ability of MSCs to alter the 
tissue microenvironment via secretion of soluble factors may contribute to tissue 
repair more significantly than their capacity for transdifferentiation (Phinney and 
Prockop 2007). 
REVIEW OF THE LITERATURE 
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1.3 Mesenchymal stem cell therapy  
Stem cells hold enormous therapeutic potential in various medical applications. 
Regenerative medicine is an emerging interdisciplinary field of research and clinical 
application. It is focused on the replacement or regeneration of human cells, tissues 
or organs, to restore or establish normal function (Mason and Dunnill 2008). The 
differentiation potential and immunomodulatory functions of MSCs have generated 
wide interest in regenerative medicine and MSCs have been hailed to revolutionize 
the field. MSCs might become an efficacious tool to treat several degenerative 
disorders, in particular those requiring the repair of damaged tissues together with an 
anti-inflammatory effect (English et al. 2010, Bernardo et al. 2012). The mechanisms 
through which MSCs exert their therapeutic potential rely on the ability of MSCs to 
secrete soluble factors capable of stimulating survival and recovery of injured cells, 
the capacity to home to damaged tissue, and to produce paracrine factors with anti-
inflammatory properties, resulting in functional recovery of the damaged tissue 
(Bernardo et al. 2012). In terms of the clinical applications of MSCs, they are being 
tested mainly in tissue regeneration, treatment of immune diseases, and enhancement 
of HSC engraftment (Helmy et al. 2010).  
1.3.1 Mesenchymal stem cells in tissue engineering 
A part of regenerative medicine is the use of MSCs in tissue engineering. Tissue 
engineering takes advantage of the combined use of cultured living cells and three-
dimensional scaffolds to deliver vital cells to the damaged site of the patient. MSCs 
have been proven effective in the treatment of bone and cartilage defects in a number 
of animal models. These include repairing bone defects of dogs with implants loaded 
with autologous MSCs (Bruder et al. 1998), skull defects of rabbits with scaffolds 
containing osteoblasts and BM-MSCs (Schantz et al. 2003), and  bone-tendon 
junction repair of rats, where MSC treatment was shown to produce better organ 
regeneration than chondrocyte treatment (Nourissat et al. 2010). MSCs have also 
been used in numerous experimental and clinical studies to treat bone and cartilage 
defects in humans. They have shown to be efficacious in the treatment of large bone 
defects (Quarto et al. 2001) and defects of articular cartilage (the smooth, white 
tissue that covers the ends of bones where they come together to form joints) 
(Wakitani et al. 2004, Haleem et al. 2010). Adipose derived MSC (ASC) products 
have been used in the treatment of bone defects such as maxillary reconstruction 
(Mesimäki et al. 2009). MSCs have also been shown to ameliorate Osteogenesis 
Imperfecta, a severe genetic disease characterized by production of defective type I 
collagen, causing fractures and retarded bone growth. The therapeutic effect was 
demonstrated by showing that after allogeneneic intravenous bone marrow 
transplantation BM-MSCs can engraft in humans and generate donor-derived 
osteoblasts that function sufficiently well for a period of time and attenuate 
biochemical, structural and clinical abnormalities associated with Osteogenesis 
Imperfecta (Horwitz et al.1999, Horwitz et al. 2001).  
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1.3.2 Immunomodulatory properties of mesenchymal stem cells 
In addition to use in tissue engineering, MSCs have generated great interest for their 
ability to display immunomodulatory effects. They may play specific roles in 
maintenance of peripheral tolerance, transplantation tolerace, autoimmunity, as well 
as tumor evasion.  
 
The anti-inflammatory effects of MSCs on many cell types on both innate and 
adaptive immune systems have been demonstrated to be broad (reviewed in Nauta 
and Fibbe 2007, Uccelli et al. 2008, and English et al. 2010). The first indications for 
the immunosuppressive nature of MSCs were obtained from the studies showing that 
MSCs were able to strongly suppress T cell activation and proliferation in vitro (Di 
Nicola et al. 2002, Bartholomew et al. 2002). In addition, MSCs have been shown to 
modulate immune response through the induction of regulatory T cells (Treg) 
(Selmani et al. 2008), a specialized subpopulation of T cells that suppress activation 
of the immune system and thereby help to maintain homeostasis and tolerance to self 
antigens. MSCs have also been shown to modulate functions of antibody-producing 
B cells by inhibiting their proliferation, differentiation, and antibody production in 
vitro (Corcione et al. 2006). MSCs suppress the differentiation of dendritic cells, 
resulting in the formation of tolerogenic immature cells that do not function as 
antigen presenting cells to T cells (Jiang et al. 2005, Nauta et al. 2006). MSCs inhibit 
proliferation and cytotoxicity of natural killer (NK) cells (Spaggiari et al. 2006). NK 
cells identify and kill allogeneic cells and their involment can have a significant 
impact on the outcome of organ transplantation. 
 
Many immunosuppressive mechanisms of MSCs have been shown to be 
mediated by soluble factors collaborating with contact-dependent mechanisms of cell 
surface receptors. MSC-mediated immunoregulation is a multilateral system that is 
mediated by several either constantly expressed or induced molecules (Uccelli et al.  
2008). Evidence is now emerging that the local microenvironment is key in the 
activation (or ‘licencing’) of MSCs to become immunosuppressive. MSCs probably 
are not spontaneously immunosuppressive, but require activation by inflammatory 
cytokines to exert their immunosuppressive effects (English 2013, Krampera 2011). 
Further in vivo studies are still required to address many aspects of therapeutically 
used MSCs, including safety concerns of especially long-term effects, engraftment 
capability and rejection. It has been speculated that rejection of allogeneic MSCs 
might be profitable in some instances, because in this way MSCs would only 
temporarily suppress the immune system, thereby reducing the risk of infection, 
malignant transformation, or suppression of a graft-versus-tumor effect (Nauta and 
Fibbe 2007).  
 
Although the mechanisms regarding how MSCs regulate immune cells in vivo 
have not been clearly defined, and controversial reports of in vitro and in vivo effects 
exist, their immunosuppressive properties have already been evaluated in 
investigational clinical settings. The most advanced clinical use of MSCs is to 
minimize the effects of steroid-resistant graft versus host disease (GvHD) caused by 
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hematopoietic stem cell transplantation (HSCT). The therapeutic effect on the 
symptoms of GvHD was first described by Le Blanc and colleagues, simultaneously 
describing the immunosuppressive effects of MSCs in vivo (Le Blanc et al. 2004). 
Similar results were also obtained by others (Kebriaei et al. 2009). Le Blanc’s group 
has also published a phase II clinical trial report assessing the influence of MSCs to 
GvHD of 55 steroid-resistant severe acute GvHD patients, and showed that MSCs 
can be transferred without HLA-matching (Le Blanc et al. 2008). Also in Finland, 
GvHD patients have been treated with MSCs. During the year 2013 The Advanced 
Cell Therapy Center of the Finnish Red Cross Blood Service supplied clinical-grade 
BM-MSC products used in the treatment of ten patients suffering from treatment 
resistant GvHD (Repo 2013 and personal communication). The immunosuppressive 
effects of MSCs have also been investigated in the treatment of Crohn’s disease, 
multiple sclerosis, type 2 diabetes mellitus, lung fibrosis, experimental autoimmune 
encephalomyelitis, and acute pancreatitis (Yi and Song 2012).  
1.3.3 Mesenchymal stem cells in clinical trials 
In February 2014 mesenchymal stem cell transplantation had been studied in 193 
clinical trials (http://clinicaltrials.org). In 2010 the amount was 105 (Helmy et al. 
2010). Helmy and colleagues have reviewed these clinical trials based on their MSC 
source, whether the MSC transplants were autologous or allogeneic, and listed a 
variety of diseases MSC transplants have been tested to treat. This data is shown in 
figure 2.  
 
 
 Summary of human clinical trials with MSCs. (a) 48 % of cells used were autologous (own) Figure 2
and 42 % allogeneic (donor). (b) MSC transplants have been tested to treat a wide variety of 
diseases. (c) Most of the MSCs used have been isolated from bone marrow (51%), but cells 
from the umbilicar cord blood (5 %) and adipose tissue (7 %) have also been used. Modified 
from Helmy et al. 2010.   
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2  GLYCOBIOLOGY 
2.1 Glycans on the cell surface  
The term glycobiology was created in the late 1980s, and is defined as the study of 
the structure, biosynthesis, biology, and evolution of glycans that are widely 
distributed in nature, and the proteins that recognize them (i.e. glycan binding 
proteins, GBPs) (Varki and Sharon 2009). Before that, in the 1960s and 1970s the 
studies of other major classes of molecules, such as DNA and proteins, developed 
rapidly, but the development on methodologies for glycan analysis lagged far 
behind.  
 
Glycomics is the study of the glycan structures of a given cell type or organism, 
i.e. the glycome. The glycome is complex and dynamic, changing in development, 
differentiation, malignancy, or inflammation. Therefore, a given cell type in a given 
species can manifest a large number of possible glycome states.  
2.1.1 Glycocalyx 
The surface of all cells is covered with a dense and complex layer of glycans called 
the glycocalyx. The diversity of glycan structures is vast and the glycocalyx is 
characteristic to and different in every cell type. Glycans respond rapidly to intrinsic 
and extrinsic signals, making the glycome of a given cell dynamic and versatile. 
Glycans are the first cellular components encountered by approaching cells, 
pathogens, antibodies, signalling molecules, and other binders. Cell surface glycans 
have vital roles in many cellular processes, such as adhesion, migration, and signal 
mediation. They are ideal molecules to be used in isolation, characterization, and 
identification of different cell populations (Lanctot et al 2007, Cummings 2009). A 
schematic view of a cell surface is presented in Figure 3.  
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 Glycan structures (shown with colourful blocks forming linear of forked structues) on the Figure 3
outer side of the cell membrane (orange bilayer) can be attached to proteins (red lumps) 
forming glycoproteins, or to lipids on the cell membrane forming glycolipids. Image: Lasse 
Rantanen / Finnish Red Cross Blood Service.  
2.1.2 Glycan structures 
Glycans on the cell surface are extremely variable and complex molecules that are 
posttranslationally added to proteins or lipids forming glycoconjucates.  The type of 
glycan is defined according to their core structure and the nature of the covalent 
linkage by which the glycan is attached to its carrier molecule. In glycoproteins, one 
or more glycans can be attached to polypeptide backbones usually via N- or O-
linkages.  
 
All N-glycans share a common core pentasaccharide (Manα1-6(Manα1-
3)Manβ1-4GlcNAcβ1-4GlcNAcβ1) and are attached to the amide group of 
asparagine residue in the consensus sequence Asn-X-Ser/Thr, where X represents 
any amino acid except proline. The N-glycan biosynthesis is complicated and highly 
conserved. N-glycans participate in the folding process and affect many properties of 
glycoproteins including their conformation, solubility, effector functions, 
antigenicity, and recognition by GBPs.  
 
O-glycans are bound to the hydroxyl group of serine or threonine residues of 
glycoproteins (Brockhausen et al. 2009). There are several types of O-glycans 
extending into a variety of different structural core classes, including α-linked N-
acetylgalactosamine (O-GalNAc), α-linked O-fucose (Fuc), β-linked O-xylose (Xyl), 
α-linked O-mannose (Man), β-linked O-N-acetylglucosamine (GlcNAc), α- or β-
linked O-galactose (Gal), and α- or β-linked O-glucose (Glc) glycans. O-GalNAc 
glycans are called mucin O-glycans and are the most common O-glycan type in 
mammalian glycoproteins. Hundreds of O-GalNAc glycans with many different 
extended structures may be attached to mucin glycoproteins. Mucins are ubicuitous 
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in body fluids and in mucous secretions on cell surfaces where they shield the cell 
surfaces and protect against infection by pathogens.  
 
Proteoglycans are glycoconjugates in which large sulfated glycosaminoglycan 
chains with unique core regions are attached to the hydroxyl groups of serine 
residues. Hyaluronan, a large nonsulfated glycosaminoglycan, does not occur 
covalently linked to proteoglycans, but can bind to them noncovalently via 
hyaluronan-binding motifs. Proteoglycans and glycosaminoglycans have many 
essential functions on the cell surface and in the extracellular matrix (Couchman and 
Pataki 2012). 
 
In addition to glycans attached to proteins, glycoconjugates can also be 
composed of glycans attached to lipids. Nearly all glycolipids in vertebrates are 
glycosphingolipids. They consist of a glycan usually attached to a lipid moiety called 
ceramide via Glc or Gal. All glycosphingolipids are synthesized from a common 
precursor, lactosylceramide (Galβ1-4GlcβCer) (Chester 1998). Sialic acid containing 
glycosphingolipids are called gangliosides. Glycosphingolipids are essential in 
development and they mediate and modulate intercellular coordination in 
multicellular organisms (Hakomori 2003). Also glycosylphosphatidylinositols (GPI) 
are a type of glycolipids that covalently attach to proteins and serve as their 
membrane anchors. Structures of the most common glycoconjugates on the cell 
surface are shown in figure 4.  
 
Although different glycan classes have unique core regions, by which they are 
distinguished, the outer structural sequences can be shared among different classes 
of glycans. These structures often determine the functions or recognition properties 
of glycoconjugates.  
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 Common classes of animal glycans. Abbreviations: mannose (Man), galactose (Gal), Figure 4
glucose (Glc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), fucose 
(Fuc), xylose (Xyl), glucuronic acid (GlcA), iduronic acid (IdoA). Terminal structure sialyl 
Lewis x (sLex) both in N- and O-glycans is highlited with a black box. Modified from Varki 
and Sharon 2009, Fuster and Esko 2005, Moremen et al. 2012.  
Additional diversity in glycoproteins is created by microheterogeneity. This 
means that all the possible glycosylation sites in the polypeptide are not necessarily 
glycosylated. Furthermore, a range of variations can be found in the structures of the 
attached glycans, so that different glycoforms of the same protein exist. The vast 
diversity existing in glycan structures emerges from the amount of monosaccharide 
residues, different linkages between them, branched structures, and modifications of 
monosaccharides, such as phosphorylation, sulfation and O-acetylation.  
 
Glycan structures present in the cell can not be predicted directly from gene 
expression. Glycosylation takes place in the endoplasmic reticulum and Golgi and 
each glycan structure is a product of sequential action of competing 
glycosyltransferases and glycosidases in a subcompartmentalized assembly-line in 
the ER and the Golgi. Therefore, the composition of glycans is affected by the 
availability of monosaccharides, and the presence of specific glycosyltransferases 
and glycosidases in the organism’s glycosylation machinery. Defects affecting 
components of the glycosylation machinery within the cell can cause severe or lethal 
developmental disorders called congenital disorders of glycosylation (Freeze and 
Schachter 2009).  
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2.2 Cellular glycobiology 
Glycans on the cell surface are optimally positioned to participate in the 
communication with the environment. Glycans have many diverse roles in various 
physiological systems, some of which are briefly described below. 
2.2.1 Blood group antigens on red cells 
At the moment there are 33 known blood group systems on the surface of red cells, 
seven of which are glycans (Reid et al. 2012). The ABO blood group of an 
individual is determined by the inherited genes coding different glycosyltransferases 
resulting in different glycan structures on red cell surfaces. The blood group A 
glycan epitope is formed by enzyme called α1-3GalNAcT encoded by the A allele of 
the ABO locus. The blood group B allele of the ABO locus encodes the α1-3GalT 
enzyme that forms the blood group B glycan determinant. O alleles at the ABO locus 
encode a functionally inactive A/B glycosyltransferase and the antigen on the cell 
surface is called the H antigen. The difference in glycan structures of blood group A 
and B is only one monosaccharide, yet the clinical relevance of this difference is 
huge. The endogenous antibodies to specific glycan structures in one person can 
cause rejection of blood transfusions from another. The terminal structures forming 
H, A, and B antigens can be part of different glycoconjugates and different core 
glycan chains in different cells. In figure 5a antigens are shown on type-2 N-
acetyllactosamines (LacNAcs), as they are present on red blood cells.  
 
Another carbohydrate blood group antigen system on red cell surface is the i/I 
antigen. The i antigen, a linear poly-LacNAc chain, is abundantly expressed on the 
surface of embryonic red blood cells. During the first 18 months of life red blood 
cells start to express branched poly-LacNAc chain, I antigen, and the level of i 
antigen declines to very low levels. This developmental regulation is presumed to be 
due to regulated expression of β1-6 N-acetylglucosaminyltransferases (I β1-
6GlcNAcT), enzymes responsible for the branching of poly-LacNAc chain. The 
expression of i/I antigens is not restricted to red blood cells and are found on N-, and 
O-glycans and on glycolipids (Cooling 2010).  
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 (a) Type-2 H, A, and B antigens that form O, A, and B blood group determinants, Figure 5
respectively. (b) Type-2 linear poly-LacNAc chain (i antigen) and branched poly-LacNAc (I 
antigen). Modified from Stanley and Cummings 2009. Blue rectangle, GlcNAc; yellow 
circle, Gal; yellow rectangle, GalNAc; red triangle, Fuc 
2.2.2 Selectins in leukocyte rolling 
Leukocytes migrate from the circulation to the inflamed tissue as part of the innate 
immune response.  Before extravasation from blood to the tissue, the rapidly moving 
leukocytes need to slow down. This step is called rolling and is highly dependent on 
glycan interactions. The endothelial cells in the inflamed tissue express P- and E-
selectins. Both of these selectins bind to a specific glycan in a glycoprotein called P-
selectin glycoprotein ligand-1 (PSGL-1), expressed on the surface of leukocytes. The 
glycan structure involved in the binding is sialic acid and fucose containing glycan 
sialyl Lewis x (sLex) on a specific core 2 O-glycan on PSGL-1. L-selectin, 
expressed on all leucocytes, is involved in leukocyte homing to secondary lymphoid 
organs and sites of inflammation. It also binds to sLex glycan, but binding specificity 
is somewhat different than the binding specificities of P-, and E selectin, e.g. 
sulfation is required for L-selectin binding. As a characteristic feature of protein-
glycan interactions, the sLex-selectin interactions are of low affinity leading to 
transient attachments of the leukocytes to the vessel wall, i.e. rolling.  Through their 
β2-integrin (CD11/CD18), slowly rolling leukocytes are able to bind to ICAM-
molecules, expressed only in the inflamed tissue endothelial cell. This protein-
protein interaction is of high affinity and allows the leukocyte to attach to the vessel 
wall and invade to the inflamed tissue (McEver et al. 1995).  
1,2
β1,4
β1,3
1,2
β1,4
β1,3
1,3
1,2
β1,4
β1,3
1,3
H antigen
A antigen
B antigen
(a) (b)
β1,4
β1,4
β1,4
β1,3
β1,3
β1,4
β1,3
β1,6
β1,4
β1,6 GlcNAcT
 25 
2.2.3 Sialyl Lewis x in fertilization 
The reproductive process is affected by glycans and GBPs. In order to the 
fertilization to occur, sperm must bind to the translucent matrix covering the oocyte, 
known as the zona pellucida. After binding, sperm must transit through this matrix to 
enter the perivitelline space, the space between the zona pellucida and the cell 
membrane of an oocyte, where they fuse with the oocyte and form a zygote. The 
interaction between mouse gametes have been shown to be glycan-mediated 
(Litscher et al. 1995, Wassarman 1990). Although a complete molecular 
understanding of human gamete binding is not yet available, it is known that the 
mammalian gamete binding is primarily mediated by the interaction of an egg-
binding protein (EBP) on the sperm plasma membrane with carbohydrate sequences 
on glycoproteins of the egg’s zona pellucida (Pang et al. 2011). It has been 
demonstatrated that the sLex is profusely expressed on human zona pellucida 
glycans and that the binding of sperm can be inhibited with soluble sLex (Pang et al. 
2011, Clark 2013). SLex is a well-known selectin ligand, but there are controversial 
reports of the expression of selectins in the human sperm. It has been suggested that 
the major egg-binding protein in sperm is very likely a lectin with a binding 
specificity that overlaps with the selectins (Pang et al. 2011). Substantial evidence 
has also implicated selectin-mediated adhesions in the early implantation of the 
embryo (Clark 2013).  
2.2.4  Cell surface glycans in microbial binding 
In order to infect host cells, microbes often use GBPs to recognize and bind to 
glycans and glycoconjugates, most commonly sialylated and fucosylated structures 
on the surface of the host cell (Imberty and Varrot 2008). The binding can be highly 
selective, demonstrated by sialic acid specific influenza viruses. The influenza virus 
hemagglutinin binds to sialic acid containing glycans on the cell surface and infects 
the cell. Human influenza A and B viruses bind to glycans terminating with α2-6-
linked N-acetylneuraminic acid (Neu5Ac), widely present on the epithelial cells of 
trachea. Chicken influenza viruses bind to glycans terminating with α2-3-linked 
Neu5Ac, and porcine influenza viruses can bind both types of the aforementioned 
linkages. In addition, influenza C virus binds exclusively to 9-O-acetylated Neu5Ac 
(Skehel and Wiley 2000). Rotavirus, the most common cause of severe diarrhea 
(gastroenteritis) among infants and young children, is another example of sialic acid 
specific viruses (Yu et al. 2012).  
 
The fucosylated ABH antigens, which constitute the molecular basis for the ABO 
blood group system, are also expressed in salivary secretions and gastrointestinal 
epithelia in individuals of positive secretor status. 20 % of caucasians are non-
secretors and do not express fucosyltransferase 2, an enzyme needed to convert type-
1 LacNAc chains to H antigens in mucus and other secretions (Imberty and Varrot 
2008). Many microbes use histo-blood group antigens in the intestinal mucus and 
other secretions as their binding targets (Wacklin et al. 2011). Norovirus, the 
common cause of viral gastroenteritis binds to H type-1 antigen and secretor 
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negative individuals are protected from the infection (Lindesmith et al. 2003). 
Secretor status is also associated with the composition of some commensial bacteria, 
such as Bifidobacteria in the human intestine (Wacklin et al. 2011).  
2.2.5 Differential glycosylation in cancer malignancy 
Glycans regulate many aspects of tumor progression, including proliferation, 
invasion, angiogenesis, and metastasis. Glycans change in malignant cells as a result 
of altered glycosyltransferase expression levels and altered location of transferases in 
the Golgi due to changes in pH (Rivinoja et al. 2009, Hassinen et al. 2011). The 
changes in glycosylation include both under- and overexpression of naturally-
occurring glycans, as well as expression of glycans normally restricted to embryonic 
tissues (reviewed in Fuster and Esko 2005, Dube and Bertozzi 2005). The common 
changes include increased β1-6-branching in N-glycans, overexpression of 
glycosphingolipids (especially gangliosides), and overexpression of some terminal 
glycan epitopes commonly found on transformed cells, such as sLex, Globo H, 
Lewis y (Ley), and Lewis a (Lea). Also mucins are overexpressed in many cancer 
cells and secreted mucins in the bloodstream can be detected by monoclonal 
antibodies as an indication of cancer. Another abnormal feature of carcinoma O-
glycans is incomplete glycosylation resulting in the expression of Tn, sialylated Tn 
(sTn), and T antigens. Increased amount of sTn is known to correlate with increased 
tumour invasiness and metastatic potential.  
 
In addition, many classes of malignant tumors express high levels of hyaluronan, 
a nonsulfated glycosaminoglycan that interacts with several cell surface receptors, 
especially CD44. These interactions are often crucial to tumor malignancy and are 
current target for novel therapies (Toole 2009, Misra et al. 2011). Also heparan 
sulfate proteoglycan (HSPG) has been implicated in tumor pathogenesis (Gomes et 
al. 2013). HSPGs can also bind and store growth factors that can be mobilized by 
tumor heparanases (Fuster and Esko 2005, Dube and Bertozzi 2005).  
 
The described chances in glycosylation are good markers of cancer and specific 
GBPs play a crucial role in cancer diagnostics. A few glycan-based targeting 
strategies have been tested in clinical trials (Fuster and Esko 2005, Dube and 
Bertozzi 2005, Toole 2009, Misra et al. 2011).  
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2.3  Glycan binding proteins 
Glycans are recognized by specific GBPs. Many of the specific biological roles of 
glycans are mediated via recognition by GBPs. They can be classified to lectins, 
glycan-specific antibodies, and glycosaminoglycan binding proteins. GBPs are an 
invaluable tool in the study of glycans, beause of their specific binding properties, 
ease of availability and manageable prices.  
2.3.1 Lectins 
 
Lectins (lat. legere; to pick out or choose / to select) are carbohydrate-specific 
agglutinins of nonimmune origin. They typically have relatively low affinities for 
single-site binding and biologically relevant lectin recognition often requires 
multivalency of both the glycan and GBP, to generate high avidity of binding. 
Lectins are found in all organisms and they have shared evolutionary origins. Many 
viral lectins are sialic acid specific and highly selective. Bacterial lectins are either 
adhesins on the bacterial cell surface that facilitate bacterial adhesion and 
colonalization, or secreted bacterial toxins (Sharon and Lis 2004).  
 
Plant lectins were found at the end of the 19
th
 century and were referred to as 
hemagglutinins, or phytoagglutinins based on their ability to agglutinate erythrocytes 
(Sharon and Lis 2004). The initial discovery dates back to 1888 when Stillmark 
found that the seeds of the castor tree (Ricinus Communis) could agglutinate red 
blood cells (H. Stillmark, 1888). This extract was called ricin and it is both an 
agglutinin and a very potent toxin. It is now known to bind to cells via interactions 
with β-linked Gal/GalNAc. In 1940s William Boyd and K.O. Renkonen made 
independent discoveries that hemagglutinins are ABO blood group specific (Boyd 
and Reguera 1949, Renkonen 1948). Morgan and Watkins later showed that the 
binding of these blood group specific lectins could be inhibited by free lectin specific 
sugars. This finding was among the earliest evidence for the presence of glycans on 
cell surfaces and indication of the potential roles of glycans as identity markers 
(Morgan and Watkins 1953).  
 
Lectins have now been found in almost every plant species studied and they are 
particularly abundant in the seeds of leguminous plants. Natural intrinsic ligands of 
plant lectins are largely unknown. The ability of plant lectins to recognize many 
animal glycans with a broad range but high degree of specificity, and their 
commercial availability, has made them an invaluable tool in the study of human 
glycans.  
 
Plant lectins were found to recognize glycans on the surface of animal cells in the 
1950s, but it took a while before endogenous lectins that recognize these glycans, 
were identified. The first mammalian lectin, galactose specific hepatic 
asialoglycoprotein receptor, was isolated 1974 (Ashwell and Morell 1974). Most 
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animal lectins can be classified on the basis of shared sequence characteristics of 
their carbohydrate recognition domains (CRDs). Several different structural families 
are known to exist, including C-type lectins (including selectins), galectins, I-type 
lectins (including siglecs). Examples of these three lectin types of great importance 
in cellular interactions are presented below. 
 
Selectins are type-1 membrane proteins having membrane-distal C-type lectin 
domain. The selectin family contains three members. L-selectin is expressed on 
mature leukocytes and HSCs, E-selectin on cytokine activated endothelial cells and 
P-selectin on the surface of activated platelets and endothelial cells. Selectins are 
crucial in lymphocyte homing, inflammation and immune responses, wound repair, 
and tumor metastasis. The transient and low-affinity glycan-selectin interactions are 
important to get the rapidly moving leukocytes to slow, which is a prerequisite for 
extravasation from blood to the inflammation site.  All selectins bind to glycans with 
terminal α2,3-linked sialic acid and α1,3-linked fucose, typified by the sialyl Lewis x 
(sLex) determinant (NeuAcα2,3Galβ1,3[Fucα1,3]GlcNAcβ1-R). The main 
physiological ligand for P-selectin is PSGL-1 containing sLex on a specific core 2 
O-glycan. PSGL-1 is expressed on leukocyte surfaces (McEver 2002).  
 
The most widely occurring family of animal lectins is galectins (formerly S-type 
lectins), so called because they bind to β-galactose containing glycoconjugates with 
their homologous CRDs of about 130 amino acids. They are found both inside and 
outside the cell and are multifunctional proteins involved in several cellular 
functions. Intracellular galectins are involved in mRNA splicing, apoptosis and the 
regulation of the cell cycle (Liu et al. 2002). Extracellular galectin functions are 
generally mediated by glycan interactions and include cell-cell, cell-matrix, and 
protein interactions through glycoprotein and glycolipid binding. These interactions 
on the cell surface can also mediate signaling inside the cell. Galectins have roles in 
immune responses and inflammation, development, and tumor metastasis 
(Rabinovich and Toscano 2009, Camby et al. 2006, Liu and Rabinovich 2005). 
Galectins lack membrane anchoring domains, but the secreted galectins can be 
tethered to their ligands in the same or adjacent cells (Stowell et al. 2009).  
 
Even though all galectins bind to β-galactose containing LacNAc structures, their 
bindin preferences are different (Stowell et al. 2008, Horlacher et al. 2010). 
Galectin-1 preferentially binds terminal LacNAc units of polylactosamines in the 
branches of multiantennary N-glycans (Camby et al. 2006, Stowell et al. 2008). 
Galectin-3 can bind both to terminal and internal LacNAc units of a glycan and its 
affinity has been shown to increase with the amount of LacNAc units, making the i 
antigen (linear poly-LacNAc) a high-affinity ligand (Stowell et al. 2008). Notably, 
MSCs express galectin-1 and galectin-3 at high levels, and they have been suggested 
to be responsible for the immunosuppressive properties of MSCs (Sioud et al. 2011). 
 
Siglecs are sialic acid binding lectins that belong to I-type lectins. I-type lectins 
are characterized by variable numbers of extracellular immunoglobulin-like domains 
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and thus belong to the immunoglobulin superfamily, other members of which are 
antibodies and T cell receptors. There are two subgroups of siglecs; human CD33 
related siglecs and conserved siglecs which in humans contain sialoadhesin (siglec-
1), CD22 (siglec-2), MAG (myelin associated glycoprotein, siglec-4), and siglec-15. 
All siglecs are type-1 membrane proteins. Siglecs show restricted pattern of 
expression in unique or related cell types. With the exception of few members, siglec 
expression has been found mainly in the hematopoietic and immune systems. For 
example siglec-2 is expressed only in B cells and regulates multiple B cell functions 
including cellular activation thresholds and survival. Each siglec has a unique 
specificity for sialylated ligands, e.g. siglec-2 is unique in having a strong preference 
for α2-6-linked sialic acids. Most siglecs on the cell surface are bound to abundantly 
expressed sialic acids on the same cell (cis interactions) and are therefore masked. 
Sialidase treatment, cellular activation or another cell or pathogen bearing higher 
affinity ligand can unmask the siglecs and result to interactions with other cells 
(trans interactions). Siglecs are thought to promote cell-cell interactions and regulate 
the functions of cells in the innate and adaptive immune systems (Crocker et al. 
2007). 
2.3.2 Glycan  specific antibodies 
 
Antibodies belong to the immunoglobulin superfamily and are produced by B cells 
as part of the immune response. Antibodies are the first line of defense against 
pathogens and remove dysfunctional or malignant cells. Each individual has 
circulating antibodies towards a vast repertoire of non-self glycan structures (Huflejt 
et al. 2009). Amongst the first well-studied anti-glycan antibodies in humans are the 
anti-blood group antibodies (Watkins 1966).  
 
Antibodies are an essential tool in the research due to their availability, high 
affinity, and specificity. Specific antibodies have had an indispensable role in the 
development of protein research. In glycan research, anti-glycan antibodies are an 
invaluable tool and widely used in glycobiology, but there are more challenges 
conserning their availability, affinity, and specificity.  
2.3.2.1 Antibody isotypes 
There are five different immunoglobulin isotypes, or classes (IgA, IgD, IgE, IgG, 
and IgM), in mammals. The isotype is dependent on B cell development and 
activation. The immunological response to carbohydrates is T cell independent, 
generally resulting in the production of IgM antibodies of low affinity. Even though 
applicable in in vitro research, IgM antibodies are not suited for in vivo diagnostics 
or therapy. Glycan specific antibodies used as research reagents are most often 
produced in mice, but can be produced in a wide variety of different animals, e.g. 
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highly specific anti-Neu5Gc antibody of IgY class produced in chicken (Nguyen et 
al. 2005, Tangvoranuntakul et al. 2003). 
2.3.2.2 Availability 
The availability of anti-glycan antibodies is far less satisfactory than the availability 
of anti-protein antibodies. This is probably due to the greater challenges in anti-
glycan antibody production and the more limited availability of carbohydrate 
antigens, which are more difficult to purify compared to proteins, and expensive and 
laborous to synthesize.   
2.3.2.3 Production 
There are several approaches to generate antibodies to glycan antigens. Hybridoma 
technology is a common method used to generate specific monoclonal antibodies. In 
this technology, mice are immunized with the carbohydrate antigen after which the 
mouse splenocytes (containing antibody producing B cells) are fused with myeloma 
cells to produce hybridoma cells. The hybridoma cells can produce uniform 
monoclonal antibodies in a cell culture, a great advantage compared to the 
production of polyclonal antibodies (Köhler and Milstein 1975, Tomita and Tsumoto 
2011). Antibodies to carbohydrate structures are more difficult to develop by 
immunization than anti-protein antibodies because carbohydrates tend to be poor 
immunogens. For this reason, mice are often immunized with natural 
glycoconjugates or glycans coupled to carrier proteins to increase their 
immunogenicity (Huhle et al. 1997, Nozaki et al. 2010), or with whole cells having 
natural glycans present as a glycoprotein, glycolipid, or proteoglycan on the cell 
surface (Numata et al. 1990, Xu et al. 2010). Mice can also be infected with parasites 
or bacteria to generate specific monoclonal antibodies to pathogen-specific glycan 
antigens (Maruyama et al. 2009). Knockout mice lacking specific glycoconjugates 
have been used to generate antibodies against the missing glycoconjugate using the 
antigen in question to immunize the mice (Chen et al. 2000). Hybridoma technology 
has been especially widely used to generate antibodies against glycan determinants 
in different types of cancer cells. The immunological response to carbohydrates is T 
cell independent, thus carbohydrate antigens produced by immunization are often 
IgM class, which limits their use in therapeutic applications.  
 
An alternative for the generation of human antibodies is antibody phage display 
technology (Schirrmann et al. 2011). It is completely independent from 
immunization and thus allows the generation of antibodies against poorly 
immunogenic molecules or even self-antigens, and uses an in vitro selection process. 
In this technology antibody phage display libraries are constructed by cloning 
amplified variable heavy (VH), variable light (VL) chains from populations of 
lymphocytes into phagemid vectors. Different combinations of these domains are 
displayed on the surfaces of filamentous bacteriophages, each displaying a single 
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antibody species. Due to limitations of the E. coli folding machinery, only antibody 
fragments like single chain variable fragment (scFv) or antigen binding fragments 
(Fabs) are used routinely for antibody phage display. The phages binding to a 
specific antigen are selected from this repertoire. In vitro isolation of antibody 
fragments from antibody gene libraries by their binding activity is called “panning”. 
Soluble antibodies having the specific binding epitope can be produced in infected 
bacteria cells and their affinity of binding can even be improved by random 
mutation, mimicking the affinity maturation in the immune system (Winter et al. 
1994). Antibody phage display technology has been successfully used to generate 
several anti-carbohydrate antibodies, such as antibodies against blood group B 
(Chang and Siegel 2001), Lewis x (Lex) and sLex (Mao et al. 1999), ganglioside 
GM3 (Lee et al. 2002), and glycosaminoglycan fragments (van Kuppevelt et al. 
1998, Smits et al. 2006). Using this technology, it has been possible to produce 
completely human monoclonal antibodies from both immune and nonimmune 
sources, rendering recombinant antibodies a promising source of tools, not only to 
basic carbohydrate research but also to diagnostic or therapeutic uses.  
2.3.2.4 Specificity 
Anti-glycan antibodies can recognize specific glycan structures in the middle of 
glycan chain or terminal epitopes. The antigen recognized can consist of several 
monosaccharides, only one monosaccharide, or both glycan and the polypeptide 
sequence of a glycoprotein or a proteoglycan. Glycan specific antibodies can be 
highly specific, e.g. antibody to Neu5Gc can distinguish betveen Neu5Ac and 
Neu5Gc differing with only one oxygen (Tangvoranuntakul et al. 2003). The specific 
epitope of antibodies recognizing the same glycan structure can be different, as has 
been demonstrated with different anti-sLex antibodies (Kannagi and Hakomori 
2001).  
 
In order to be used as a tool in research or therapeutic applications, the specificity 
of a GBP need to be accurately and precisely determined, but detailed epitope 
characterization of anti-glycan antibodies and lectins can be challenging. Methods to 
analyze the GBP specificity include X-ray crystallography, nuclear magnetic 
resonance (NMR) spectroscopy, isothermal calorimetry, mono- or oligosaccharide 
inhibition studies, ELISA-type assays and glycan based microarrays.  
2.4 Use of glycan binding proteins 
2.4.1 Glycan binding proteins as reagents in the study of glycans 
Lectins and anti-glycan antibodies are widely used tools in glycobiology. They are 
mostly used as research reagents in many glycobiological applications such as in the 
identification of glycans and enrichment and purification of glycoproteins. Lectins 
are generally cheaper than antibodies, and many lectins currently used as tools in 
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glycobiology come from plants and are commercially available. Most lectins have 
broad specificity and are primarily used to monitor general changes of carbohydrate 
expression. For example Concanavalin A (ConA) binds only to N-glycans and has 
highest affinity to oligomannose type.  However, some lectins have highly accurate 
binding specificities demonstrated with lectins differentiating between A and B 
blood group antigens or between α2,3- and α2,6-linked sialic acids. The advantage of 
antibodies is that unlike lectins, they can be produced against desired glycan 
structures. Antibodies generally have high specificity for their antigens, but different 
antibodies to same glycan structures can have different binding epitopes and 
affinities (Kannagi and Hakomori 2001). This is why the specificity should be 
accurately determined in order to use the binder to produce high quality information.  
 
The expression levels of glycans are difficult to determine using methods such as 
gene expression analysis, since glycans are not direct gene products. The presence 
and amount of glycans in cells or tissues have primarily been monitored indirectly by 
probing the binding of anti-glycan antibodies and lectins by immunochemistry, flow 
cytometry and Western blotting (Manimala et al. 2007). Glycolipids can be detected 
by using GBPs in thin layer chromatography. Flow cytometry using specific GBPs 
or magnetic beads coupled to GBPs can be used to isolate and sort cells from 
heterogenous samples. The multivalency of some GBPs can be used to agglutinate 
cells bearing specific glycan antigens. GBPs are also commonly used in affinity 
chromatography methods, such as lectin columns, to enrich the glycoprotein before 
mass spectrometric analysis.  
2.4.2 Glycan binding proteins in diagnostics and therapy 
The use of GBPs in diagnostics and therapy is much more limited than their use as 
research reagents. There is a tremendous potential of GBPs to be valuable diagnostic 
and therapeutic tools in the future, but it is proven to be very challenging to develop 
these agents. In order for this to happen, the function mechanism of glycans needs to 
be elucidated more, and the general glycobiological expertise needs to be improved 
even more. However, some GBPs are currently used in diagnostics and several 
antibodies have already been tested in clinical trials of antibody based therapy 
(Glennie and Johnson 2000). Some of the glycan markers and GBPs used in 
diagnostics are described below.  
 
One of the best known expamples of GBPs in diagnostic is the ability of lectins 
to recognize blood group antigens on the cell surface (Renkonen 1948). Blood 
banks, including FRC Blood Service, use specific anti-glycan antibodies to 
determine groups of red cells. However, some lectins are still used as a back-up 
strategy in routine blood group screenings.  
 
The other diagnostic use of GBPs with enormous potential is the cancer 
diagnostics. Glycosylation changes in cancer cells compared to normal healthy cells, 
and specific glycan markers for cancer have been identified (see section 2.2.5) 
 33 
(Fuster and Esko 2005). The serological markers CA125, CA19-9, and CA 15-3 are 
mucin glycoconjugates commonly overexpressed in ovarian, pancreatic, and breast 
cancers, respectively. Although these and other glycan markers are currently used 
clinically as sensitive markers for recurrence of disease following initial treatment, 
they might also be used to facilitate the timing of glycan-based therapies in future 
cancer treatment programmes (Fuster and Esko 2005).  
 
The other example of clinically relevant glycome change in cancer is the human 
chorionic gonadotropin (hCG), a glycoprotein hormone normally produced during 
pregnancy. It is also expressed in certain malignancies, especially by trophoblastic 
and testicular germ cell tumors, for which hCG is a sensitive marker. The 
glycosylation of hCG is different in cancer and pregnancy and the glycoform 
expressed in malignancy is called “hyperglycosylated”. A specific monoclonal 
antibody B152 used to recognize the hyperglycosylated hCG specifically recognizes 
a core-2 glycan on Ser-132 and on surrounding peptide structures in malignancy 
associated variant of hCG. A lectin assay detecting increased fucosylation could also 
be used in the diagnostic (Valmu et al. 2006).  
 
The carbohydrate deficient transferrin (s-CDT) has been reported to be one of the 
best laboratory markers in serum for detection of alcohol abuse. Transferrin is a 
glycoprotein synthestized mainly in the liver. It has two N-glycans containing sialyl 
residues, tetrasialotransferrin being the most common form. The transferrin 
glycoforms were originally thought to represent deficiencies in the terminal 
sialylation (hence the nomenclature). However, these modifications are now known 
to be more extensive such that entire glycan chains are absent reflecting a more 
profound effect of alcohol upon liver glycosylation mechanisms (Valmu et al. 2005, 
Flahault et al. 2003).  Immunonephelometric method used to determine the amount 
of s-CDT is based on the measurement of scattered light which determines the size, 
shape, and concentration of the scattering particles, in this case the antigen-antibody 
complexes. Specific antibody recognizing the change in glycosylation is used in the 
assay (Delanghe et al. 2007).  
2.4.3 Challenges related to glycan binding proteins  
The quality of the information obtained from antibody and lectin-binding studies 
depends largely on the specificity of the binders. Even though possessing great 
potential as research reagents and in diagnostics, improvements are needed in the 
determination of specificity of GBPs. In addition to accurate specificity, the affinity 
of most carbohydrate-binding antibodies should be enhanced. When monitoring 
carbohydrate expression for diagnostic purposes, different studies frequently report 
conflicting results. As a result, only a small number of carbohydrate antigens are 
used clinically as biomarkers (Manimala et al. 2007).  
 
It is generally known that glycan antibodies are difficult to generate and may 
display broad specificity. A carbohydrate microarray profiling of 27 commercially 
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available antibodies with known specificities demonstrated that many of the 
antibodies displayed inappropriate binding relative to the listed specificity.  More 
than half of the antibodies studied crossreacted with other glycans on the array 
(Manimala et al. 2007). The problem with specificity determination is that some 
anti-glycan antibodies may recognize their antigens only in a specific context, such 
as on cell surface as part of specific glycoconjugates. A high-throughput microarray 
analysis has also been performed with 24 lectins and it showed some unexpected 
binding properties. However, lectins frequently exhibit secondary binding 
requirements beyond simple mono- or disaccharide specificity, making their 
specificity hard to analyze (Manimala et al. 2006). 
 
Stage-specific embryonic antigens SSEA-3 and -4 are among the most commonly 
used markers to identify embryonic stem cells. SSEA-3 (Galβ1-3GalNAcβ1-3Galα1-
4Galβ1-4Glc) is a precursor molecule for SSEA-4 (Neu5Acα2-3Galβ1-3GalNAcβ1-
3Galα1-4Galβ1-4Glc). The most commonly used anti-SSEA-4 antibody (clone 
MC813-70) has been reported to cross react with GM1b and GD1a 
glycosphingolipids, with terminal epitope Neu5Acα2-3Galβ1-3GalNAc (Kannagi et 
al. 1983). These glycosphingolipids (GSLs) have been shown to be present both in 
ESCs and in cells differentiated from them (Liang et al. 2010, Liang et al. 2011), 
suggesting that this anti-SSEA antibody may not be the best one to detect 
undifferentiated embryonic stem cells.  This highlights the importance of knowing 
what other antigens the antibody binds in addition to the one it is generated against. 
Strategies combining different methods, such as GBPs in flow cytometry or 
immunostaining combined with mass spectrometric analysis, can be used to verify 
results obtained with only one method (Liang et al. 2010, Liang et al. 2011).  
 
It has also been reported that there is considerable heterogeneity in the 
carbohydrate specificity of anti-sLex antibodies, which adds complexity to selectin-
mediated adhesion analyses. SLex determinants can be part of different glycan 
chains, have differentially bound sialic acids or have additional sulfate 
modifications. Different antibodies recognize these slightly different epitopes 
differently. Some anti-sLex antibodies also cross react with closely related sLea 
structure (Kannagi and Hakomori 2001). 
 
Antibody specificity variations in glycans binding can have significant 
implications for biomarker performance as demonstrated comparing five different 
sLea antibodies used in pancreatic cancer detection. Glycan array analysis revealed 
that certain antibodies were highly specific for the sialyl Lewis a (CA19-9) epitope, 
while others bound also a related but non-fucosylated structure called sialyl Lewis c. 
The use of antibody with broader specificity led to the detection of an increased 
number of pancreatic cancer patients without increasing the detection of pancreatitis 
(Partyka et al. 2012). This highlights the value of both characterizing the accurate 
specificity of antibodies and other binders, as well as detecting the accurate antigens 
elevated in cancer or other disease conditions.  
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3 GLYCANS IN STEM CELL BIOLOGY 
3.1 The glycan markers of stem cells 
Glycans in the glycocalyx comprise a prominent molecule class on the cell surface, 
which is why many commonly used stem cell surface markers are glycoproteins, 
glycolipids, and proteoglycans. Enzymes involved in the glycan synthesis can also 
be used as markers.  
3.1.1 Glycome profile  
The glycome profile of a cell is characteristic to a certain stem cell type and can be 
used to identify different kinds of stem cells. Mass spectrometry has been used in the 
analysis of the glycome profile of different types of stem cells. A study comparing 
the N-glycans of undifferentiated human ECSs and their differentiated progeny 
demonstrated that the N-glycome on the cell surface reflects cell’s differentiation 
stage (Satomaa et al. 2009). It was seen that the most characteristic glycosylation 
feature in the undifferentiated human ESCs was complex fucosylated structures, i.e. 
fucoses in the antennae of N-glycans, such as Lex and H type 2 antennae in 
sialylated complex-type N-glycans. The N-glycan structures of HSCs have also been 
analyzed with mass spectrometric profiling (Hemmoranta et al. 2007). Human 
hematopoietic stem cells (CD133+) were shown to have enriched amount of 
biantennary complex-type N-glycans, high-mannose-type N-glycans and increased 
terminal α2-3-sialylation level compared to progenitor cells (CD133-). Information 
from the glycan profiles is useful when identifying stem cells from differentiated 
progenitor cells and also when developing future strategies regarding stem cell 
targeting.  
3.1.2 Surface antigens 
Individual glycan structures are commonly used markers when identifying specific 
cell types. GBPs are commonly used tools to analyze specific cell surface glycan 
determinants, commonly in flow cytometric analysis or immunofluorescent staining. 
GBPs can also be used in a wide variety of different methods, such as affinity 
chromatography and ELISA-based methodology, or in enrichment of cell 
populations known to have certain glycan antigens on their surface. Panels of surface 
markers can be used to monitor differentiation status of stem cells. Human ESCs can 
be characterized with a panel of pluripotency associated cell surface markers, 
including glycan antigens SSEA-3, SSEA-4, Tra-1-60, and Tra-1-81 (International 
Stem Cell Initiative et al. 2007). Also MSCs are characterized by a panel of markers 
suggested by ISCT (Dominici et al. 2006). These markers are almost all 
glycoproteins. Whether these glycoproteins need to be correctly glycosylated in 
order for MSC to have specific functions remains still unknown. The heavily 
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glycosylated sialomucin molecule CD34 is commonly used marker for human 
hematopoietic stem cells. CD133 is another cell-surface glycoprotein used to identify 
human HSCs, although it seems to identify a slightly different and more primitive 
subset of HSCs than CD34 (Hemmoranta et al. 2006). CD133 is also used to identify 
and purify multipotent neural stem cells (Uchida et al. 2000). 
 
Human ESCs have specific glycosphingolipid (GSL) profiles (Liang et al. 2010, 
Liang et al. 2011). Patterns of GSL expression change greatly during development 
and differentiation. In mass spectrometric analysis, human ESCs have been shown to 
have globo- and lacto-series GSLs on their surface, but the cells switch to ganglio-
series GSLs when they differentiate. The switch was shown to be the result of altered 
expression of glycosyltransferases in the biosynthetic pathways of the GSLs (Liang 
et al. 2010). Lactoseries GSLs found on human ESCs include fucosyl Lc4Cer 
(Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4GlcCer), bearing H type 1 antigen (underlined 
in the structure), which is the precursor of A, B, and Lewis blood group antigens. H-
type 1 epitope is present in undifferentiated ESCs and disappears during 
differentiation (Liang et al. 2010). Commonly used ESC markers SSEA-3 and 
SSEA-4 are epitopes on the globo-series GSLs, termed GL-5 and GL-7 (Kannagi et 
al. 1983). SSEA-3 and SSEA-4 are found to be present in ESCs and their amount 
decreases rapidly upon differentiation (Liang et al. 2010). Even though the amount 
of SSEA-3 and SSEA-4 on the ESC surface diminishes when the cell differentiates, 
it has been shown that they are not essential for the maintenance of human ESC 
pluripotency (Brimble et al. 2007).  
 
Sialic acids are typically found at the outermost end of glycan antennae and 
sialylated structures on various macromolecules are recognized by many cell-type-
specific antibodies. Polysialylated neural cell adhesion molecule (PSA-NCAM) is a 
glycoprotein and a prominent cell-surface glycan marker. PSA is a quite unique 
carbohydrate structure composing of linear homopolymer of α2-8-linked-N-
acetylneuraminic acid and it’s presence on NCAM is developmentally regulated. 
PSA-NCAM is involved in many aspects of neurogenesis and plasticity (Bonfanti 
2006).  
 
The tumor-rejection antigens (Tra) are widely used markers of ESCs. The 
monoclonal antibodies Tra-1-60 and Tra-1-81 are known to recognize carbohydrate 
epitopes and are routinely used to assess the pluripotency status of human ESCs and 
iPS cells (International Stem Cell Initiative et al. 2007). It has been suggested that 
both antibodies recognize keratan sulfate proteoglygan, but the binding of Tra-1-60 
is dependent on sialic acids, and binding of Tra-1-81 is not (Badcock et al.1999). 
However, the glycan array analysis suggested specific binding of Tra-1-60 and Tra-
1-81 to terminal type-1 lactosamine epitopes present in human ESCs as part of a 
mucin-type O-glycan structure (Natunen et al. 2011). 
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3.1.3 Glycosyltransferases 
In addition to cell surface antigens, glycosyltransferases involved in the glycan 
synthesis can also be used as stem cell markers. The mRNA expression of 
glycosyltransferase genes can be measured and used as an indication of the 
differentiation state of the cell. The N-glycan biosynthesis pathway is composed of 
sequential addition (or removal) of monosaccharides in the form of nucleotide 
sugars, each catalyzed by a specific glycosyltransferase (or glycosidase). The 
expression level of specific glycosyltransferases defines the glycan structures present 
on the cell surface.  
 
In a study comparing the N-glycan structures and associated gene expression in 
human hematopoietic stem and progenitor cells, many stem cell specific transferases 
and corresponding glycan structures were determined (Hemmoranta et al. 2007). 
MGAT2 gene, encoding GlcNAcT2 glycosyltransferase, was shown to be 
overexpressed in undifferentiated HSCs. This enzyme catalyzed the addition of 
GlcNAc residue to the second antenna of the forming N-glycan, an essential step in 
the conversion from oligomannose- to complex-type N-glycans. As a result of this 
enzyme activity, biantennary complex-type N-glycans were enriched in HSCs. Also, 
the MGAT4 gene, encoding GlcNAcT4 was shown to be underexpressed in HSCs 
compared to progenitor cells. GlcNAcT4 catalyzes the addition of GlcNAc residue 
to a mannose residue in the forming N-glycan, resulting in the formation of 
triantennary N-glycans. HSCs were also shown to have elevated α2-3 sialylation, 
supported by the overexpression of ST3GAL6 gene encoding α2-3 sialyltransferase. 
Another sialyltransferase, α2-6 sialyltransferase competes for the same substrates 
with α2-3 sialyltransferase and the sialylation type in the N-glycan surface is a result 
of the expression level of specific sialyltransferases.  
 
It was seen from the N-glycan profile of the human ESCs that the most 
characteristic glycosylation feature in the undifferentiated human ESCs was complex 
fucosylated structures. Fucosyltransferase genes FUT1, -2, -4 and -8 were shown to 
be expressed in human ESCs. When compared to differentiated embryoid body cells 
FUT1 and FUT4 were overexpressed. Lex and H type-2 structures formed by the 
action of glycosyltransferases encoded by FUT4 and FUT1, respectively, were 
clearly recognized from the profile (Satomaa et al. 2009).  
 
SSEA-4, a widely used marker of ESCs has also been seen in the surface of 
MSCs derived from cord blood (Suila et al. 2011). The gene expression analysis 
showed that the expression of ST3Gal-II, which is the SSEA-4 synthase, was clearly 
elevated, correlating well with the amount of SSEA-4 on the cell surface. 
 
In addition to determining of the expression of individual glycosyltransferase 
enzymes and the corresponding glycan structures, the development of more thorough 
transcript profiling methods has been started. The transcript profiling of glycan-
related genes has its own set of complexities and mapping enzymes to complex 
glycan biosynthetic pathways for glycoprotein, glycolipid and proteoglycan 
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biosynthesis and catabolism are still in their early stages. The fact that many of the 
critical enzymes involved in the glycan modifications are encoded by a relatively 
low amount of transcripts, brings additional complexity to the study of glycan-
related gene expression. However, some analytical platforms have been developed 
(Nairn et al. 2010, Nairn et al. 2012).  
3.2 Role of glycans in stem cell cultures 
Cell culture is a crucial step that can have dramatic effect on cells, especially to the 
antigens on the cell surface. Bone marrow transplantations are normally done 
without any cultivation of the HSCs, but in the development of advanced cellular 
therapy produts, such as MSCs, the cells are isolated, expanded and maybe even 
manipulated before used in the future therapeutic approaches. Therapeutic cells 
should optimally be cultivated in xeno-free conditions, meaning animal derived 
materials should not be used. Changes in the glycans on the cell surface are a good 
indication of the use of animal derived materials during the culture.   
3.2.1 Lectin as embryonal stem cell culture matrix 
Human embryonic stem cells used to be, and still often are, cultured using fetal 
mouse fibroblasts as feeder cells. The use of mouse fibroblast feeder cells inhibits 
the spontaneous differentiation of human ESCs in vitro and removal of the feeder 
cells leads to enhanced differentiation (Reubinoff et al. 2000). Optimal feeder-free 
culture matrices for human ESCs have been under development and include 
Matrigel
TM
, or laminin-coated plates and conditioned mouse feeder-cell medium (Xu 
et al. 2001). These approaches both have some challenges since they contain animal 
derived materials compromising potential clinical applications. ESCs have also 
successfully been cultured on xeno-free systems containing human-derived feeder 
cells. Human fetal and adult fibroblast feeders from human fetal muscle, fetal skin, 
and adult fallopian tubal epithelial cells have been shown to support prolonged 
undifferentiated human ESCs (Richards et al. 2002).  
 
Since glycans on the cell surface have important roles interacting with the cell’s 
environment, lectins binding to the glycan epitopes commonly found from the 
human ESC surface could be considered as an optimal culture matrix (Mikkola et al. 
2013). Indeed, Erythrina cristacalli agglutinin (ECA), specific for type 2 LacNAc 
structures, was shown to support the self-renewal capacity of the cells in long-term 
culture. The expression of pluripotency markers and functional characteristics of the 
cells cultured on ECA were comparable to cells on Matrigel
TM
.  ECA introduces as a 
fully defined, promising and, cost-effective cell culture matrix for human ESCs.  
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3.2.2 Non-human glycans in cultured stem cells 
The culture media of many cells typically contain fetal calf or bovine serum 
(FCS/FBS), or in some cases horse serum. Human ESCs and MSCs are commonly 
cultured in the presence of animal-derived materials for research purposes. When 
stem cells are cultured for therapeutic applications, animal derived medium 
components need to be replaced. However, the clinical efficacy of MSCs in human 
diseases has been investigated using MSCs cultured with FCS in a number of 
clinical trials (Horwitz et al. 2002, Bang et al. 2005). The animal derived 
components in the culture medium of cells have been shown to alter the 
glycosylation. Human ESCs grown in contact with mouse feeder cells and animal-
derived cell culture medium components have Neu5Gc on their surface (Martin et al. 
2005). The two most common mammalian sialic acids are Neu5Gc and Neu5Ac, 
with Neu5Ac being the metabolic precursor of Neu5Gc. As a consecuence of 
inactivating mutation in CMP-N-acetylneuraminic acid hydroxylase (CMAH) 
enzyme, Neu5Gc is not present in humans (Varki 2001). Neu5Ac differs structurally 
from Neu5Gc with only a single oxygen atom. Human cells can take Neu5Gc from 
cell culture and cell separation reagents such as FCS, serum replacement, and bovine 
serum albumin (BSA) (Martin et al. 2005). In addition to stem cell cultures, human 
cells take up Neu5Gc from their surroundings containing animal products of even 
from dietary sources such as red meat and milk products, and metabolically 
incorporate it to the forming glycans using the same Golgi transporter and 
sialyltransferases as CMP-Neu5Ac (Tangvoranuntakul et al. 2003, Bardor et al. 
2005). The human immune system recognizes Neu5Gc as a foreign and produces 
circulating anti-Neu5Gc antibodies (Tangvoranuntakul et al. 2003, Martin et al. 
2005). Thus, using stem cells cultivated in the presence of animal derived material 
could compromise transplantation success by inducing an immune response. It has 
been reported that the Neu5Gc xenoantigen contamination in human ESCs as well as 
in MSCs is reversible, and Neu5Gc can not be detected from the cell surface after 
the cells are transferred to animal-free culture conditions (Heiskanen et al. 2007). 
The Neu5Gc content of cultured human cell lines and their secreted glycoproteins 
can also be reduced by adding excess of Neu5Ac to the culture medium (Ghaderi et 
al. 2010).  
 
Other non-human glycan detected in human ESCs is the α-galactosyl epitope (α-
Gal). Human and other primate cells do not express the α1-3 galactosyltransferase 
capable of making the linkage (Macher and Galili 2008). α-Gal is highly 
immunogenic and humans have natural preformed antibodies against the epitope. α-
galactosyl epitope is present on mouse fibroblast feeder cells used in ESC cultures. 
The epitope is not metabolically incorporated into human cells but carried along into 
hESC preparations (unpublished results).  
 
Because of the immunogenic nature of non-human glycan structures, they 
introduce remarkable risk in stem cell transplantation.  
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3.2.3 Metabolic glycoengineering 
As cell surface glycosylation is affected by the culture conditions, the properties of 
therapeutic cells can be manipulated through metabolic glycoengineering. In this 
technique monosaccharide analogs are added to culture medium through which they 
are introduced into the metabolic pathways of a cell and are biosynthetically 
incorporated into the glycocalyx. However, it has been shown that adding unnatural 
sialic acid precursor can influence not only the sialic acid composition of cell surface 
glycans, but also the overall N-glycan profile of the cells (Natunen et al. 2013). 
These changes may affect the properties of MSCs and need to be considered when 
the glycosylation is manipulated, but when carefully controlled, could also be 
utilized for example in the optimization of stem cell biodistribution.  
3.3 Glycosylation in stem cell biodistribution 
Glycosylated structures on the cell surface have vital roles in many cellular 
processes such as adhesion, migration, proliferation, and signal mediation (reviewed 
in Lanctot et al. 2007, Cummings 2009). A major issue in the use of various types of 
stem cells for regenerative therapy is to achieve sufficient localization of the cells to 
the desired sites of tissue damage.  
 
Homing is the process by which cells migrate to, and engraft in, the tissue in 
which they can excert their local functions. Cell migration involves a cascade of 
events initiated by adhesive interactions between flowing cells and the vascular 
endothelium at the target tissue. These interactions result in cell-tethering and rolling 
contacts on the endothelial surface, typically followed by chemokine-triggered 
activation of integrin adhesiveness, firm adhesion, and extravasation (Sackstein 
2005).  
3.3.1 Glycans in hematopoietic stem cell homing 
Transplanted HSCs engraft the bone marrow and migrate to the sites of damage, 
such as stroke and myocardial infarction, by means of the concerted action of 
specific surface molecules that mediate homing from vascular to tissue 
compartments. Similarly to leukocytes, the migration of HSCs is selectin dependent 
(Hidalgo et al. 2002). Selectin ligands expressed in HSCs are PSGL-1 and HCELL 
(hematopoietic cell E-/L-selectin ligand), a specific glycoform of CD44 
glycoprotein. PSGL-1 is expressed on various mature leukocytes, on several 
hematopoietic cell lines, and on primitive human hematopoietic stem and progenitor 
cells. HCELL expression is characteristic only for primitive hematopoietic cells 
(Dimitroff et al. 2001). Both PSGL-1 and HCELL have terminal sLex (Neu5Acα2-
3Galβ1-4(Fucα1-3)GlcNAc) structures, mediating the interaction with selectins 
(Foxall et al. 1992). In PSGL-1 the sLex epitopes are in O-glycans and in HCELL in 
N-glycans (Sackstein 2004). It has been noticed that impaired fucosylation of the cell 
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surface glycans results in the lack of rolling and homing of the cells (Xia et al. 2004, 
Hidalgo and Frenette 2005).  
3.3.2 Glycans in mesenchymal stem cell homing 
MSCs have been shown to home to site of the injury or inflammation and to produce 
paracrine factors with anti-inflammatory properties, resulting in functional recovery 
of the damaged tissue (Salem and Thiemermann 2010). The mechanisms of MSC 
migration is not as well known as the mechanisms of leukocyte or HSC homing. 
MSCs are a heterogenous population of cells, which causes controversy in the results 
of studies involving “homing receptors” of MSCs. It has been shown that only a 
small portion of MSCs in one transfusion experiment had the capacity to home to 
bone marrow (Wynn et al. 2004). Different sources of MSCs can also have 
differences in the expression of surface antigens causing variability to homing 
procedure and creating additional controversy to the results (Nystedt et al. 2013). It 
is also good to keep in mind that the surface structures of the cells are dynamic and 
differences in culture conditions, such as plating density, confluence, passage 
number, and cytokine supplements cause alterations and make it more challenging to 
compare different cell products.  
 
MSCs have been shown to express many protein surface antigens involved in the 
homing cascade, including integrins, chemokine reseptors, and CD44 (Henschler et 
al. 2008, Qu et al. 2014). However, unlike with leukocytes and HSCs, the role of 
selectins in MSC homing remains elusive. MSCs have been shown to display 
coordinated rolling and adhesion behavior in a P-selectin dependent manner. The P-
selectin ligand in MSCs is still undefined, since these cells have shown not to have 
the expected ligand, PSGL-1, bearing sLex on a specific core 2 O-glycan, on their 
surface (Rüster et al. 2006). A recent study suggests a novel interaction between two 
lectins, P-selectin and galectin-1 on UCB-MSCs (Suila et al. 2014). Whether this 
interaction is dependent on carbohydrates and the lectin properties of these two 
proteins needs further elucidation.  
 
MSCs have also been shown to lack the expression of E-selectin ligands 
(Sackstein et al. 2008). MSCs do have CD44 on their surface, but a different 
glycoform than HCELL in HSCs. The glycans of the CD44 in MSCs have terminal 
α2-3 sialic acids linked to galactoses, but they lack the α1-3-linked fucose 
modifications on GlcNAc residues needed to form sLex (Neu5Acα2-3Galβ1-
4(Fucα1-3)GlcNAcβ1-R), a vital part of the epitope binding to E-selectin. Treating 
MSCs with fucosyltransferase VI (FTIV) to create HCELL has been shown to result 
in E-selectin-mediated homing of intravenously injected human MSCs to bone 
(Sackstein et al. 2008) and prime the cells  for transendothelial migration, which is 
needed for entry into the site of inflammation or injury in any intravenous 
application (Thankamony and Sackstein 2011). The rolling response of human 
MSCs both on P-selectin coated substrates in vitro and on inflamed endothelium in 
vivo has also been achieved by chemically incorporating sLex to the cell surface 
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(Sarkar et al. 2011). MSCs derived from the umbilical cord blood (UCB-MSCs) 
have been reported to have higher fucosylation level and more sLex on their surface 
than MSCs derived from bone marrow (BM-MSCs) (Nystedt et al. 2013). This and 
other differences in the adhesion molecules on these two MSC types were shown to 
influence the biodistribution of the cells.  
 
In addition to carrying glycan ligands essential to selectin-mediated homing of 
MSCs, CD44 can also function as a lectin that binds hyaluronan, a large nonsulfated 
glygosaminoglycan (Lesley et al. 2000, Qu et al. 2014). The CD44-hyaluronan 
interaction has been shown to mediate the migration of MSCs into wound sites (Zhu 
et al. 2006, Bian et al. 2013).   
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4 AIMS OF THE STUDY 
Glycosylation on the cell surface is a characteristic and cell-type specific feature of 
all cells, and GBPs are a valuable tool in the characterization of the cell-surface 
glycans. Novel stem cell markers and well characterized GBPs binding them are 
needed in the research of stem cell glycosylation as well as in therapy applications.  
 
The purpose of this thesis was to characterize and develop glycan binding 
proteins keeping in view of their use as tools in MSC therapy. The specific aims 
were:  
 
 characterization of glycans on the surface of mesenchymal stem cells 
 
 scrutinizing different GBPs, including 8 lectins and 69 antibodies, in the 
characterization of MSCs 
 
 characterization of linear poly-LacNAc, i.e. the i antigen, as a UCB-MSC 
marker 
 
 production of i blood group antigen (i.e. linear poly-LacNAc) -specific 
antibody with recombinant technology 
 
 production of MSC surface glycan specific antibodies with whole cell 
immunization and hybridoma technology 
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5 MATERIALS AND METHODS 
5.1 Methods 
The materials and methods used in this study are described in detail in the original 
publications and listed in Table 1. The original publications are referred to using 
their Roman numerals I-IV.  
 Materials and methods used in the study Table 1.
Method Used in study 
MSC culture 
- preparation of MSC lines from BM or UCB 
- MSC differentiation 
- enzymatic treatment of cell surface proteins and glycans 
- chemical derivatization of cell surface glycans 
I, II, III, IV 
I, II, III, IV 
I, II, III, IV 
I, II, III, IV 
IV 
Isolation of red blood cells III 
Flow cytometry I, II, III, IV 
Immunofluorescence staining and microscopy I, II, III 
mRNA expression analysis II 
Amino acid sequence analysis and comparison III 
Mass spectrometry 
- glycan and glycoprotein isolation for mass spectrometry 
- mass spectrometric analysis of lipid linked-, N- and O-
glycans of the cell 
- mass spectrometric analysis of cell surface N-glycans 
mass spectrometric data analysis 
I, II 
I, II 
I 
 
II 
I, II 
Phage display antibody production 
- construction of scFv phage display libraries 
- selection and screening of recombinant antibodies 
- preparation of phage clones 
III 
III 
III 
III 
- red blood cell agglutination assay III 
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Oligosaccharide competition assay II, III 
Hybridoma technology for antibody production 
- immunization of mice 
- hybridoma cell preparation and culture 
- monocloning of hybridomas 
IV 
IIV 
IV  
IV 
- Dissociation-enhanced lanthanide fluorescent 
immunoassay (DELFIA) 
IV 
 
5.2 Ethics 
This study was approved by the ethical review board of the Finnish Red Cross Blood 
Service and Helsinki University Hospital (statement numbers 550/E8/02 and 
235/13/03/00/2011). Umbilical cord blood was obtained after normal vaginal 
delivery with full consent of informed and healthy volunteers at the Helsinki 
University Central Hospital, Department of Obstetrics and Gynecology, and Helsinki 
Maternity Hospital. Only UCB units unsuitable for therapeutic use were used in 
these studies. The most common reason for discharging UCB units for therapeutic 
use was a small total volume or a low total number of cells. 
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6 RESULTS 
The main results of the studies are summarised here. The results are presented and 
discussed in detail in the accompanying original publications, which are referred to 
using their Roman numerals I-IV.  
6.1 Characterization of mesenchymal stem cell 
glycome (I, II) 
Stem cell glycosylation has been shown to have unique features. However, the 
majority of the studies have concentrated on embryonic stem cells (Muramatsu and 
Muramatsu 2004). We wanted to widen the research on human stem cell 
glycosylation into MSCs. To get a comprehensive conception of the cellular 
glycome of MSCs, we combined mass spectrometric profiling and GBP analysis to 
study MSCs both from bone marrow (I) and from umbilical cord blood (II).  
 
First the glycome profiles of both BM-MSCs and corresponding osteogenically 
differentiated cells were analyzed. Comparison of the profiles revealed that the stem 
cells and osteoblasts both have characteristic glycosylation features and that the 
glycome changes during osteogenic differentiation occur in a predetermined fashion. 
The mass spectrometric analysis showed that high-mannose N-glycan structures and 
fucosylated acidic O-glycans were more dominant in stem cells than in differentiated 
osteoblasts. All major glycosphingolipid classes were found in both MSCs and 
differentiated osteoblasts, but MSCs expressed more small ganglio-type glycans than 
osteoblasts. Further analysis revealed that MSC N-glycans contain fucosylated 
terminal structures, such as Lex. Also sialylation, mainly α2-3-linked sialic acid, was 
shown to be a typical structure on MSCs. It was also shown that MSCs have linear 
poly-LacNAcs in N- and O-glycans and possibly also in glycosphingolipids. This 
structure was not seen in differentiated osteoblasts. Differentiated osteoblasts 
contained more complex- and hybrid-type N-glycans, sulfate modifications, and 
larger glycosphingolipids than undifferentiated MSCs.  
 
Since the mass spectrometric profiling of MSC glycome encompassed the overall 
cellular glycome, including intracellular glycans, further verification of cell surface 
presentation of the observed glycan structures was obtained by cell surface 
cytochemical staining and flow cytometric analysis with GBPs, either lectins or 
antibodies. In agreement with the mass spectrometric data, MSCs were shown to 
contain more mannosylated structures than their osteogenic counterparts, shown with 
Hippeastrum hybrid lectin (HHA) staining.  The Solanum tuberosum lectin (STA) 
recognizing mainly linear-poly-LacNAc chains was shown to pronouncedly stain 
MSCs (I, Figure 5c,d), verifying the mass spectrometric result. GBP analysis also 
clearly showed that MSCs have increased amount of sialyl Lewis x on their surface, 
compared to differentiated cells (I, Figure 5a,b and figure 6 c,d). This is in good 
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agreement with the findings of the mass spectrometric analyses showing fucosylated 
and α2-3-sialylated structures in both N- and O-glycans. In flow cytometric analysis, 
MSCs, but not differentiated cells, were also shown to have SSEA-4 on their surface 
(I, Figure 6a,b). SSEA-4 is a widely used embryonic stem cell marker, also observed 
in MSCs (Suila et al. 2011). However, SSEA-4 was not observed in mass 
spectrometric analysis. The analysis of glycome profiles and the verification of 
glycan structures are more thoroughly presented in publication I.  Table 2 shows 
examples of the glycans enriched in undifferentiated mesenchymal stem cells.   
 
 The glycans enriched in undifferentiated mesenchymal stem cells.  Only one high-mannose Table 2.
type structure is shown in the table, even though structures with different number of 
mannose residues were seen in the profile. Green circle, Man; blue rectangle, GlcNAc; 
yellow circle, Gal; yellow rectangle, GalNAc; purple diamond, Neu5Ac; blue circle, Glc; 
red triangle, Fuc.   
Glycan enriched in MSCs Glycan structure 
High-mannose type 
 
Linear poly-N-acetyllactosamines 
 
SSEA-4 
 
Shorter ganglioside structures 
(e.g. GM3, GD3) 
 
Sialyl Lewis x 
 
α2-3-linked sialic acids  
 
 
We also performed a mass spectrometric analysis of MSCs derived from 
umbilical cord blood and made verifications with GBPs (unpublished data, except 
for linear-poly-LacNAc shown next, II).  
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6.2 The i antigen on the surface of 
mesenchymal stem cells (I, II) 
One of the most interesting findings in the glycan profile of BM-MSCs was that 
linear poly-LacNAc structures, also called the i antigen, are present on 
undifferentiated BM-MSCs but not on osteoblasts differentiated from them (I, Figure 
3 and Figure 5 c,d). We next showed that the i antigen is also present on the surface 
of UCB-MSCs. The N-glycans on the surface of UCB-MSCs were analyzed by mass 
spectrometry and found to include linear di-LacNAc epitope (II, Figure 4).  
 
The expression of i antigen was more thoroughly characterized with GBPs. The 
lectin binding properties of UCB-MSCs were studied with different LacNAc binding 
lectins. The Solanum tuberosum agglutinin (STA), Lycopersicon esculentum 
agglutinin (LEA) and Datura stramonium agglutinin (DSA) lectins mainly recognize 
linear poly-LacNAc structures. In flow cytometric analysis they all strongly stained 
UCB-MSCs (98-100 %), indicating the presence of i antigen on the cell surface in 
great amounts (II Figure 1). STA lectin recognized epitopes also on BM-MSCs in 
cytochemical staining, whereas the osteogenically differentiated cells were hardly 
recognized (I fig 5). UCB-MSCs were also shown to have some amount of branched 
poly-LacNAc structures (the I antigens) on their surface, indicated by the staining 
with Phytolacca Americana agglutinin (PWA) recognizing mainly branched poly-
LacNAc structures (II figure 1). Also, 80% of the UCB-MSCs stained positive for 
terminal LacNAc stuctures with Erythrina cristacalli agglutinin (ECA) (II, figure 1). 
Chitotriose (GlcNAc3) inhibited the binding of STA, DSA, LEA and PWA, verifying 
the specificity of lectin stainings (II, data not shown).  
 
Galectins are a family of animal lectins that bind to LacNAc structures. Galectin-
3 can bind both to terminal and internal LacNAc units of a glycan and its affinity 
increases with the amount of LacNAc units, making the i antigen (poly-LacNAc) a 
high-affinity ligand (Stowell et al. 2008).We studied the expression of galectin-3 in 
UCB-MSCs and observed notable mRNA expression of galectin-3. The relative gene 
expression level of galectin-3 was found to be significantly higher than the relative 
gene expression levels of the studied MSC markers (II, figure 6a). Galectin-3 on 
UCB-MSC surface was also detected by mass spectrometry and flow cytometry (II, 
figure 6b,c).   
 
To obtain further evidence of the presence of i antigen on UCB-MSC surface, we 
stained the cells with polyclonal human serum containing anti-i IgM 
immunoglobulins. Flow cytometric analysis revealed that 42-98% of the UCB-MSCs 
stained positive with anti-i serum in repeated experiments (II, figure2 a, b). We also 
discovered that even though anti-i serum strongly stains UCB-MSCs, both the 
osteogenic and adipogenic cells differentiated from them were almost unstained (II, 
figure 3). This is in good agreement with our findings of the MS analyses showing 
the enrichment of i antigen on BM-MSCs, but not in osteogenic cells differentiated 
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from them (I). The fact that i antigen is present only in undifferentiated 
mesenchymal stem cells could indicate its potential role as a marker of stemness.  
 
To confirm that the anti-i serum recognizes linear poly-LacNAc structures, UCB-
MSCs were treated with endo-β-galactosidase, an enzyme that hydrolyses internal β-
galactosidic linkages of linear poly-LacNAc structures. The enzyme treatment 
drastically diminished the amount of cells stained with the anti-i serum (from 98% to 
48%), indicating the disappearance of linear poly-LacNAc structures (II, figure 2c). 
Results of the presence of linear-poly LacNAc on UCB-MSC surface are combined 
on figure 6.   
 
 Summary of the analysis of linear-poly LacNAc antigen (i blood group) on UCB-MSC Figure 6
surface. Polyclonal anti-i serum stains most of the cells in flow cytometric analysis. The 
staining is drastically diminished when cells are treated with endo-beta-galactosidase that 
cleaves linear poly-LacNAc chains. Cells differentiated to osteogenic (OG) or adipogenic 
(AD) progenitor cells are not stained more than the cells stained with control serum not 
recognizing the i antigen. The data is a compilation of independent flow cytometric 
experiments and the error bars represent differences within each experiment.  
Furthermore, we showed that several specific glycosyltransferases involved in 
the synthesis of linear poly-LacNAc structures are expressed in UCB-MSCs (II, 
figure 5).  
6.3 Production of glycan binding proteins (III, 
IV) 
Few anti-i antibodies have been produced in the 80s and 90s (Feizi et al. 1980, 
Fenderson et al. 1986, Hirohashi et al. 1986, Miyake et al. 1989, Nagatsuka et al. 
1995), but none of them are commercially available anymore. None of the antibodies 
produced are not available anymore. Since the production of an anti-glycan antibody 
is not as easy as the production of anti-protein antibodies, we decided to approach it 
with two different techniques (summarized in table 3). The first approach was to 
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make a specific anti-i recombinant antibody with phage display technology (III), and 
the second approach was to make a mesenchymal stem cell surface specific 
monoclonal anti-glycan antibody with whole cell immunization technology (IV).  
 
The challenge in anti-i antibody production was to find a blood donor with an 
elevated serum anti-i titer. Detection of a suitable donor made it possible to construct 
IgM phage display libraries from donor lymphocytes (III, figure 1). Since synthetic 
glycans do not necessarily exactly resemble the naturally occurring glycan chains in 
the cell surface, we used red blood cells having the natural antigens on their surface 
to select the potential anti-i binders from the libraries. Umbilical cord blood -derived 
red blood cells, which naturally have the i antigen on their surface were used in the 
selection, and adult-derived red blood cells, naturally having the I antigen on their 
surface, were used in the depletion of the libraries (figure 7). 
 
 
By using naturally occurring glycan chains, we wanted to avert the possibility 
that the antibodies selected using synthetic glycan would not recognize the intended 
antigen in the form that is present on cell surface. After four affinity selection 
rounds, about 100 scFv phages enriched to i-positive red blood cells and further 
characterization provided one that recognized the i antigen on UCB-MSCs (III).  
 
 
 Red blood cells used in the selection of scFv clones from antibody phage display libraries.  Figure 7
Our another objective was to produce and characterize monoclonal antibodies 
against UCB-MSC surface glycans with hybridoma technology. We used intact 
UCB-MSCs to immunize mice and selected glycan-specific antibodies produced by 
hybridoma cells. Using whole cells in the immunization, it is possible to produce 
antibodies against previously unknown carbohydrate antigens, specific for the cell 
type in question.  
 
From the 250 hybridoma culture medium samples containing polyclonal 
antibodies, five were able to bind to UCB-MSC structures in DELFIA binding assay, 
three of which were shown to be glycan specific by enzymatic and chemical 
treatment of glycans. During the monocloning, antibody production of one of the 
polyclonal hybridoma cultures ceased and we ended up with two monoclonal MSC 
surface glycan specific antibodies (IV, table 1).  
I Ag on 
adult red 
blood cells
Used in depletion 
of unwanted 
phages
i Ag on UCB 
derived red 
blood cells
Used in 
enrichment of 
positive phages
AB O
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6.4 Epitope determination of glycan binding 
proteins (II, III, IV) 
The specificity of a binder is the most crucial character that has to be accurately and 
precisely determined. However, detailed epitope characterization on GBPs is 
challenging.  
6.4.1 Enzymatic and chemical cell surface modification (II, II, IV) 
As mentioned above (6.2), the specificity of the anti-i serum was demonstrated by 
treating the cells with endo-β-galactosidase, an enzyme that hydrolyses internal β-
galactosidic linkages of linear poly-LacNAc structures (II). The dramatic decrease of 
the antiserum binding level demonstrated that the serum recognizes linear poly-
LacNAc structures, i.e. the i antigens (figure 6 and II figure 2c). Enzymatic treatment 
of cell surface molecules was also used when examining the capability of 
prospective anti-i scFv antibodies to agglutinate the i antigen containing UCB- 
derived red blood cells (III). To enhance the agglutination efficiency and improve 
carbohydrate accessibility, red blood cells were enzymatically treated with sialidase 
and papain. Sialidase was selected to remove terminal sialic acids and make repeated 
lactosamine structures more accessible. However, this treatment was observed 
unnecessary for the induction of agglutination. In contrast, treatment with papain, a 
cysteine protease catalyzing the breakdown of proteins, showed that removal of bulk 
cell surface proteins was critical for the binding of scFv antibodies to red blood cells 
(III, table 3). Agglutination assays comparing the ability of prospective anti-i scFv 
antibodies to agglutinate i antigen containing UCB-derived red blood cells but not 
adult red blood cells that don’t have the i antigen on their surface, were essential in 
the determination of i antigen specific antibodies (III).  
 
When producing MSC surface glycan specific antibodies, we enzymatically 
removed the cell surface glycans in order to study which antibodies lose the binding 
to their cognate antigens after removal of the glycans (IV). In order to 
comprehensively remove different cell surface glycan structures, we used a cocktail 
of wide variety of enzymes. PNGase F is an endoglycosidase and was used to release 
N-linked oligosaccharides. O-glycosidase was used to release unsubstituted Ser- and 
Thr-linked βGal-(1-3)αGalNAc (core 1 type O-glycan) from glycoproteins. Broad 
specificity neuraminidase capable of hydrolyzing different types of sialic acid 
linkages was used to remove the sialic acids, and β1-4 galactosidase to release β1-4-
linked galactose from the non-reducing end of complex oligosaccharides. β-N-
acetylglucosaminidase was used to liberate terminal β-linked N-acetylglucosamine 
and α1-(3,-4) fucosidase to release antennal α1,3-fucose and α1,4-fucose from 
complex carbohydrates. Removal of cell surface glycans clearly affected the binding 
of three of the tested antibodies, but the variations between replicates were quite 
large. Therefore, we subsequently chemically modified the cell surface glycans with 
periodate oxidation. Mild periodate oxidation at acidic pH leads to conversion of 
vicinal hydroxyl groups of glycan chains to reactive aldehyde groups without 
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altering the structure of polypeptide chains. As the treatment opens the carbohydrate 
ring, it alters the binding determinants enough to prevent the binding of 
carbohydrate-specific antibodies. We used 5mM periodate to modify terminal 
glycans on the MSC surface enabling us to identify three carbohydrate binding and 
two non-carbohydrate binding antibodies in a DELFIA assay (IV, figure 1). The 
three carbohydrate binding antibodies were the same as those identified with 
enzymatic treatment.  
 
All carbohydrate antigenic determinants are not sensitive to periodate treatment. 
Determinants consisting of linear carbohydrate chains with linkages at carbon 3, 
such as the i antigen, are considered not to be periodate sensitive (Woodward et al. 
1985, Niemann et al. 1978). This explains why we did not see any effect of the 
periodate treatment of UCB-MSCs on the binding of prospective anti-i antibodies 
(III).  
6.4.2 Competition binding assay (III) 
To find out if the epitope recognized by the prospective anti-i antibodies is a linear 
polylactosamine, we performed a competition binding assay with three different 
lactosamine oligosaccharides (III). A flow cytometric analysis showed that the linear 
lactosamine containing two LacNAc units and a lactose unit inhibited the cellular 
binding of all three prospective anti-i antibodies tested (III, figure 5).  
6.4.3 Glycan array (III, IV) 
Array formats containing vast variety of different glycans have been developed to 
test the specificity of GBPs. We tried to screen the carbohydrate specificity of the 
developed recombinant antibodies, but were not very succesful with this method. 
The prospective anti-i antibodies as scFv hyperphages were sent to the Consortium 
for Functional Glycomics (CFG) glycan array containing 611 different glycan 
structures. We did not get any spesificities to our binders, but this might be a 
methodological issue, since the array is optimized for antibodies, not hyperphages 
(III). Also the two antibodies produced with hybridoma technology were sent to the 
CFG glycan array, but the very low relative fluorescence signal level of the results 
did not relate to significant binding to any of the glycans. However, if the antibodies 
were to recognize both glycan and a peptide epitope, or a glycosaminoglycan 
epitope, this would not be seen in the CFG glycan array (IV).  
6.4.4 Sequence analysis and comparison (III) 
The serum antibodies that bind the i antigen belong to cold agglutinins (Pascual et al. 
1992). An immunoglobulin VH4.21 gene segment has been shown to be required to 
encode anti-i and anti-I specificities (Pascual et al. 1992, Schutte et al. 1993, Smith 
et al. 1995). The similarity of all five prospective anti-i antibodies was between 64 % 
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and 83 % compared to VH4.21 gene segment (III, figure 2). The antibody having 
highly similar amino acid sequence (83%) was shown to be the most promising anti-i 
antibody also in other specificity experiments (III).  
6.4.5 The occurrence of the epitope (I, II, III, IV) 
Antigens on cell surface can be characteristic to a certain cell type or to a certain 
stage of the cell development. We showed that glycan antigens on BM-MSC, the 
glycan profile, is characteristic to this cell type and changes when the cell 
differentiates (I).  
 
As the i antigen is known to be present in red blood cells derived from umbilical 
cord blood, but not in adult red blood cells, this feature was used to identify and 
isolate anti-i antibodies from all the antibodies in the phage display library (II). The i 
antigen was also shown to be present on MSC surface, but not on the surface of 
osteogenic or adipogenic cells differentiated from MSCs (II, figure 3). This revealed 
that the i antigen can be used as a MSC marker (II). When producing the anti-i 
antibody, we utilized this quality to select the i antigen binding antibodies (III, figure 
4).    
 
Many glycans are known to be species specific. Our monoclonal antibodies were 
produced using UCB-MSCs in the immunization. The binding to other cell types 
was observed and the two antibodies also recognized human BM-MSCs, but did not 
recognize porcine BM-MSCs. Neither did they regognize human HT-29 cancer cells 
or human fibroblasts, one of the end products of mesenchymal differentiation (IV, 
table 2).   
 
One indirect way to get information of the glycan antigen recognized by an 
antibody is to study if the antigen epitope is in a glycoprotein, glycolipid, or 
proteoglycan. The protease sensitivity of our two monoclonal antibodies produced 
with hybridoma technology was studied by detaching the UCB-MSCs from culture 
plates with pronase or trypsin with varying duration and temperature of treatment. 
Flow cytometric analysis showed that the binding of both antibodies was highly 
sensitive to treatment with both proteases. Pronase treatment abolished the binding 
totally and trypsin treatment significantly, depending on the circumstances (IV, 
figure 2). This indicates that these antibodies might be epitopes in glycoproteins or 
in proteoglycans.  
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 Summary of the production of anti-glycan antibodies.  Table 3.
Produced 
antibody 
Production 
method 
Antibody 
type 
Antigen Antigen specificity 
determination 
Anti-i Ab  
(III) 
Phage display 
technology 
(i/I panning) 
Recombinant 
Ab 
(hyperphage) 
linear poly-
LacNAc  
(i antigen) 
 red blood cell 
agglutination assay 
 DNA sequencing 
 Oligosaccharide 
competition 
binding assay 
 
Anti-
MSC  
Ab1 (IV) 
Hybridoma 
technology 
(MSC 
immunization) 
Monoclonal 
Ab  
(IgG1κ)                           
MSC surface 
glycoprotein 
or 
proteoglycan 
 Glycosidase 
treatment of cell 
surface glycans 
(mixture of 
different 
glycosidases) 
 Chemical 
derivatization of 
cell surface glycans 
(periodate)  
 Protease treatment 
(pronase) 
 
Anti-
MSC  
Ab2 (IV) 
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DISCUSSION 
Glycobiology is a fast developing field of interest studying glycans, molecules 
vitally involved in every aspect of life. Glycans were once considered merely as 
decorative elements serving simply structural and energy requirements in a cell. 
Perhaps the most important reason why the progress in glycobiological research was 
not as rapid as the progress and enthusiasm in the study of other macromolecules lies 
in the structural complexity of glycans. However, over the last few decades, new 
technologies have been developed which have been proven very powerful in 
glycobiological research (reviewed in Cummings 2009, Varki and Sharon 2009). 
 
Antibodies have played a significant role in the field of protein research and they 
are widely used in the identification and purification of proteins. GBPs are used in 
glycobiological research in multiple different methods, such as ELISA, glycan 
arrays, cytochemical staining, and flow cytometry. The use of GBPs is usually cost-
efficient and method development and validation are relatively easy compared to e.g. 
NMR and mass spectrometry. However, there are some challenges with the use of 
GBPs (Kannagi and Hakomori 2001, Manimala et al. 2006, Manimala et al. 2007, 
Liang et al. 2010, Liang et al. 2011). Glycans are poor immunogens often resulting 
to glycan specific antibodies with weak affinity. Furthermore, the specificity of 
GBPs is challenging to determine accurately and precisely. The specificities of 
commercially available GBPs are not always accurate and should not be blindly 
trusted (Manimala et al. 2006, Manimala 2007, Partyka et al. 2012). At the moment, 
the results obtained with GBPs should always be verified with other methods to 
avoid misinterpretation of the data (Liang et al. 2011). The contradictory results 
between different methods in the same study or between different research groups 
are likely due to either cell line specific expression of the epitope, differences in the 
cell isolation or in culture conditions, or differences in the handling of the cells 
required for different methods. Different binding characterics of GBPs in solid-phase 
methods, such as glycan arrays and ELISA, compared to binding of ligands on cells 
or in solution, also cause differing results.  
Glycans are potential biological biomarkers to be used in stem cell 
characterization and therapy 
Glycans play important roles in a vast array of biological processes, such as 
fertilization, bacterial and viral infections, inflammation, and cancer metastasis 
(Lanctot et al. 2007). The vast diversity of glycan structures changes rapidly and 
continuously, responding to intrinsic and extrinsic signals (Cummings 2009). 
Glycans are at the center of many disorders and diseases, making them important 
research object both for therapeutic and diagnostic purposes. Realizing the potential 
and promise that glycobiology holds, many pharma and biotech companies are 
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novadays allocating their research and development resources to it, glycan 
engineered therapeutic antibodies as one example.  
 
Another therapeutically interesting field is stem cell research. Stem cells hold 
enormous therapeutic potential in various medical applications. MSCs are currently 
in a focus of intense clinical and scientific investigation. They are a promising cell 
type for various applications in the field of tissue engineering as well as an attractive 
candidate for therapy of several immune-mediated disorders (Kirkpatrick et al. 2014, 
English et al. 2010, Bernardo et al. 2012). Unlike HSCs, MSCs are cultured before 
transplantation to a patient. This makes them biological drugs (called advanced 
therapy medicinal product, ATMP), controlled by regulatory authorities and 
requiring marketing authorization. The European Medicines Agency (EMA, 
www.ema.eu) evaluates and supervises medicinal products in Europe, and in Finland 
this is regulated by the Finnish Medicines Agency (Fimea, www.fimea.fi). 
 
The glycans on the cell surface are ideal molecules for identification, 
purification, and characterization of cells for therapeutic purposes (Lanctot et al. 
2007). The effects of culture conditions are seen rapidly on the glycosylation and 
glycans can even be manipulated to change e.g. the biodistribution of the cell 
(Nystedt et al. 2013).  For these purposes, methods are needed to reliably and 
proficiently determine the cell surface glycans. GBPs in general serve as diagnostic 
tools in medical and scientific laboratories. High affinity and exquisite specificity are 
important factors for their successful use.  
 
In this thesis, our first aim was to analyze the glycome of MSCs and to find novel 
MSC specific markers. The research was then expanded into developing GBPs for 
both stem cell and glycobiological research, keeping in mind the therapeutic 
applications for both fields.    
Stem cell surface glycans are characteristic to a cell type 
We first analyzed the glycome of MSCs and compared it to the glycome profile 
of osteogenically differentiated cells (I). Combination of techniques to complement 
and verify the results were used. It has been a well-tried practice to combine 
especially the data from mass spectometry and GBPs to get more reliable results 
(Liang et al. 2010, Liang et al. 2011). Our data clearly indicates that MSCs have a 
specific glycosylation pattern that changes when the cell differentiates, thus the 
glycome profile analysis can be used to evaluate MSC differentiation state. 
Corresponding results have been obtained from the analysis of ESC (Satomaa et al. 
2009) and HSC (Hemmoranta et al. 2007) N-glycomes with mass spectrometry. The 
glycome analysis also revealed other interesting findings, including the increased 
expression of linear poly-LacNAc in MSCs compared to osteoblasts differentiated 
from them. This finding was observed by mass spectrometric fragmentation analysis, 
digestion with endo-β-galactosidase (an enzyme that specifically cleaves linear poly-
LacNAc), and staining with GBP, a lectin called STA. Poly-LacNAcs are known to 
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be expressed in red blood cells in a developmentally regulated manner (Cooling 
2010). Linear poly-LacNAc chains (i antigen) in fetal blood cells are changed to 
branched chains (I antigen) in the adult.  Poly-LacNAc structures are ligands for 
galectins and thus involved in cell adhesion, microbe-host interactions, and 
modulation of immune responses (Rabinovich and Toscano 2009).  
Linear poly-N-acetyllactosamine (i antigen) is a marker for 
mesenchymal stem cells 
The expression of linear poly-LacNAc was further studied in UCB-MSCs and 
based on the findings, we suggested it as novel marker for these cells (II). Again, a 
combination of methods was used to confirm the results. Multiple different GBPs 
were used to recognize the linear poly-LacNAc structure on the cell surface. Lectins 
specific for linear poly-LacNAc structures, STA, LEA, and DSA, all recognized the 
structure. Also a polyclonal patient serum containing anti-i IgM recognized the 
specific structure on flow cytometric analysis. The same serum is used in blood 
group serology. This antiserum failed to recognize the cells after treatment with 
endo-β-galactosidase, indicating that it specifically recognizes the linear poly-
LacNAc structure. Mass spectrometric and mRNA expression analysis supported the 
results obtained with GBPs.  Often the best and most reliable result is obtained when 
the mass spectrometric glycan profile data is combined with data from GBP studies 
and verified with the gene expression analysis of glycosyltransferase expression. 
Linear poly-LacNAc (the i antigen) is developmentally regulated in red blood cells, 
but the expression of the i and I antigens in other tissues has been noticed not to 
correlate with the red blood cell phenotype (Thomas 1974, Cooling 2010). However, 
this study shows that the expression of linear poly-LacNAc structures in MSCs is 
similar to red blood cells and is regulated according to cell differentiation. 
Undifferentiated MSCs have linear poly-LacNAc structures on their surface, but 
these structures are not expressed on the surface of cells differentiated along 
adipogenic or osteogenic lineages. Therefore, linear poly-LacNAc can be used as a 
novel MSC marker.  
 
There are currently no commercially available antibodies recognizing the linear 
poly-LacNAc antigen. In blood group serology, the typing of i antigen on red blood 
cells is typically performed using polyclonal human antisera, expressing the antibody 
with high enough titer. None of the anti-i antibodies, listed in Glyco Epitope 
database (www.glyco.is.ritsumei.ac.jp/epitope), are available anymore (personal 
communication with the corresponding writers of Feizi et al. 1980, Fenderson et al. 
1986, Hirohashi et al. 1986, Miyake et al. 1989, Nagatsuka et al. 1995). Since an 
anti-i antibody could be useful both in the identification of MSCs aimed at therapy 
and in blood group serology, we decided to develop our own anti-i antibody (III). 
Antibody phage display technology to generate recombinant antibodies was used, to 
avoid problems realated to poor immunogenicity of glycans. This technology has 
been succesfully used to generate several anti-glycan antibodies, including antibody 
against blood group B (Chang and Siegel 2001). Similar to the study of Chang and 
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colleagues (Chang and Siegel 2001), we used red blood cells in the panning, to find 
the specific binders for the antigen in question. In the production and 
characterization of the binders, they were used in multiple different methods, 
including agglutination assay, flow cytometric analysis, and competition binding 
assay. Characterization of potential binders resulted in the selection of one 
prominent antibody specific for linear poly-LacNAc structure.  
Mesenchymal stem cell surface glycans introduce other alternative 
markers 
We also used an alternative strategy to generate novel MSC surface glycan specific 
antibodies (IV). Glycans are known to be poor immunogens, but the immunogenicity 
increases when glycans are presented as glycoconjucates, i.e. glycoproteins, 
glycolipids, or proteoglycans (Fuster and Esko 2005). In this study, we used intact 
UCB-MSCs to immunize mice and selected glycan specific antibodies produced by 
hybridoma cells. The glycan specificity was analyzed using periodate oxidation, 
where glycans on the antigens are oxidized preventing the glycan specific antibody 
to bind its cognate antigen (Woodward et al. 1985). Using whole cells in the 
immunization process, it is possible to produce antibodies against previously 
unknown, natural antigens, specific for the cell type in question. Typically antibodies 
produced by immunization are IgM class, and therefore not well applicable for in 
vivo diagnostics or therapy (Ravn et al. 2004). However, IgG antibodies from 
immunization are also known to occur. Both of the two antibodies produced in this 
study were IgG class. The produced GBPs were used in different methods, such as 
DELFIA microplate method, flow cytometry, and glycan array, to confirm the 
results.   
 
In the studies (III and IV) presented in this thesis, we were succesful in 
generating carbohydrate specific antibodies. These antibodies could be used in stem 
cell research as well as in therapeutic applications. However, the characterization of 
these GBPs has had many challenges, as has been noticed in many previous studies 
(Kannagi and Hakomori 2001, Manimala et al. 2006, Manimala et al. 2007, Liang et 
al. 2010, Liang et al. 2011, Partyka et al. 2012). There are different methods with 
different advantages for characterization of protein-glycan interactions. ELISA-type 
solid-phase methods using GBPs are easy and cost-effective to develop, but are 
laborous and require large amounts of both glycans and GBPs. This problem might 
be alleviated with the progress of methods to synthesize glycans. Other methods with 
same shortcomings are NMR spectroscopy and X-ray chrystallography which also 
require special equipment and trained personnel (Manimala et al. 2007). Glycan 
microarrays are a relatively new technology for high-throughput screening of 
glycan-GBP interactions. Glycan arrays contain a huge variety of glycans and 
require much less GBPs than other, more traditional methods. A publicly available 
glycan microarray has been introduced by the Consortium for Functional Glycomics 
(www.functionalglycomics.org). In our studies, we sent both the recombinant 
antibodies (III) and monoclonal antibodies produced by immunization (IV) to be 
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analyzed with this glycan array. Unfortunately, we did not get any results for either 
set of antibodies. Our recombinant antibodies sent were in the form of hyperphages 
and it is currently unclear ir this glycan array is a suitable method for assaying 
glycan-binding specificity of hyperphages since there is no previous experience in 
successfully using this technology for hyperphages. Also, the monoclonal glycan-
specific antibodies produced by immunization did not bind significantly to any of the 
glycan structures on the array. This gave us reason to believe that our antibodies bind 
either to glycosaminoglycan structures missing from the array or both to the glycan 
and the underlying peptide sequence of a glycoprotein or a proteoglycan. The 
disadvantage of glycan arrays is that they vary in ligand presentation, the glycans are 
not necessarily presented in the form as they occur naturally (isolated glycans vs. 
chemically synthesized), and assay conditions and detection methods can affect the 
binding or the observed result. Also the immobilization of the glycans on the flat 
surfaces can modify the recognition capability of GBPs. All these features contribute 
to the affinity and selectivity of binding, and thus the assay may not reflect the actual 
conditions and binding on the cell surface (Manimala et al. 2007, Leppänen and 
Cummings 2010).  
Future prospects in stem cell glycomics 
Applications using MSCs in therapy are gaining incremental interest. Their 
capability to suppress immune mediated diseases like GvHD has already been 
proven in practice (Le Blanc et al. 2004, Kebriaei et al. 2009, Le Blanc et al. 2008). 
However, the naturally ununiform population of MSCs, different tissues of origin 
and variations in culture protocols between different research institutions, lead to 
slightly different populations of MSCs, even though the cells would fulfill the 
minimal criteria for MSCs (Dominici et al.2006).  
 
There has been progress in gaining better understanding of the role of glycans in 
biological processes, earlier hindered by technical limitations in the glycobiological 
field. Glycans on the cell surface are prominent structures and ideal markers for 
cells. Methods to analyze glycans need to become widely accessible also to 
researchers who are not specialists in carbohydrate chemistry, mass spectrometry or 
NMR. Use of GBPs is easily accessible in many methods, such as cytochemical 
staining, flow cytometry, or affinity chromatography. The challenges to overcome 
with GBPs are the poor availability, broad specificity, and low affinity. GBPs are not 
readily available for numerous glycan structures that exist in nature. The production 
and characterization of exact specificity are still challenging and the affinity between 
glycans and proteins is naturally weak. It may take some years until good enough 
tools to routinely analyze glycan stuctures on the stem cell surfaces are in wide use 
in diagnoctic and therapeutic applications. But it is promising that the utmost 
importance of cell surface glycans has been started to be understood in all aspects of 
cellular biology, not just among glycobiologists.  
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